| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Xtant Medical Holdings, Inc.$0.42
0 (-0.02%)
F 17Pipeline Score MedTech · Commercial
Market Cap
67.33 M
EPS
0.01
P/E Ratio
44.04 $
Value Trade
22.67 K
SEC Financials
Q1 2026Dilution Risk
35%Revenue
20.88 M
R&D Expenses
435.00 K
Operating CF
-2.11 M
Total Assets
78.00 M
Total Liabilities
29.40 M
Equity
48.60 M
D/E Ratio
12,345
2.78 %
Week
-10.73 %
1 Month
-17.38 %
3 Month
-25.44 %
6 Month
-67.57 %
5 Year
-99.84 %
All Time
Cash Data
Cash Position
12.16 M
Monthly Burn
705.00 K
Runway
15.5 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
9.67 K
52 Week Range
0.44 - 0.95
% held by Insiders
13.84 %
% held by Institutions
57.56 %
Enterprise Value
70.61 M
Total Shares
140.43 M
Short %
0.01 %
Float Shares
48.45 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 14%
Micro Cap (rank 784 of 911)
Percentile RankXtant Medical Holdings, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XTNT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XTNT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XTNTXtant Medical Reports First Quarter 2026 Financial Results
Xtant Medical reported its first quarter 2026 financial results, revealing a revenue of $20.9 million, down from $32.9 million in Q1 2025. The company raised its full-year revenue guidance to $101-$105 million, bolstered by a new distribution agreement with Dilon Technologies. Despite a net loss of $3.1 million, Xtant's balance sheet has improved significantly.
Read more →XTNTXtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
Xtant Medical Holdings, Inc. has announced that it will be releasing its financial results for the first quarter of 2026 on May 13, 2026. The announcement includes details of a conference call to be hosted by key executives, Sean Browne and Scott Neils, at 8:30 AM ET on the same day. This release is part of the company's regular updates to its stakeholders and aims to provide insights into its financial performance in the orthopedic market.
Read more →XTNTXtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
Xtant Medical has launched Trivium Shaped, an extension of its bone graft portfolio designed for surgical applications. This new product offers pre-shaped configurations to enhance consistency and efficiency in the operating room. The launch reflects Xtant's commitment to innovation in orthobiologics, utilizing PureLoc technology for improved graft performance.
Read more →XTNTXtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant Medical has secured exclusive U.S. distribution rights for Dilon Technologies' HEMOBLAST® Bellows, a hemostatic product. This partnership aims to enhance Xtant's offerings and expand its market reach. The integration of Dilon's sales team is expected to bolster Xtant's commercial capabilities significantly. The companies believe this collaboration will address the needs of surgeons and patients effectively.
Read more →XTNTXtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial
Xtant Medical, in collaboration with the Montana Governor's Office of Community Service, announced support for the Threshold of Life Memorial. This memorial will honor organ, eye, and tissue donors and is set to be installed at the Montana State Capitol by Summer 2028. The initiative aims to raise awareness and inspire future donor registrations.
Read more →XTNTXtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Xtant Medical reported a strong financial performance for 2025, with revenues reaching $133.9 million, a 14% increase from the previous year. The company achieved profitability and positive cash flow, bolstered by strategic divestitures and a focus on its biologics business. Looking ahead, Xtant anticipates continued growth in 2026 despite the cessation of some license revenues.
Read more →XTNTXtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
Xtant Medical Holdings, Inc. will release its financial results for Q4 and the full year of 2025 on March 31, 2026. The announcement includes details for a conference call led by CEO Sean Browne and CFO Scott Neils. This event aims to provide insights into the company's performance and future outlook.
Read more →XTNTXtant Medical Finalizes Companion Spine Transactions
Xtant Medical has finalized transactions with Companion Spine, receiving $10.7 million related to the sale of its Coflex® assets and Paradigm OUS businesses. This payment brings the total purchase price for the divestitures to $21.4 million. The funds will help reduce long-term debt and increase liquidity, allowing Xtant to concentrate on its biologics business.
Read more →XTNTXtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
Xtant Medical Holdings, Inc. will participate in the Canaccord Genuity 2026 Musculoskeletal Conference on March 2, 2026. Key executives, including CEO Sean Browne, will present and engage in virtual one-on-one meetings with investors. A webcast of the presentation will be accessible starting February 2, 2026, and a replay will be available for 90 days.
Read more →XTNTXtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
Xtant Medical has launched its next-generation synthetic bone graft, nanOss Strata, designed to mimic human bone structure and enhance healing. Made from hydroxycarbonapatite, it offers improved bioactivity and osteoconductivity. The product is available in various forms and aims to improve surgical outcomes for patients. CEO Sean Browne emphasizes the company's commitment to innovation in regenerative medicine.
Read more →XTNTXTANT MEDICAL HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated financial information was derived from the historical consolidated fi
Xtant Medical Holdings, Inc. has released its unaudited pro forma condensed consolidated financial information following the divestiture of its subsidiary, Paradigm Spine GmbH, aimed at optimizing its business structure. The divestiture is expected to reduce the company's term loan significantly, potentially enhancing its financial position. Although the pro forma statements are meant for informational purposes only, they reflect adjustments due to the divestiture process. The report warns that these projections should not be construed as indicators of future financial results.
Read more →XTNTXtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine
Xtant Medical Holdings has completed the sale of its Coflex® assets and Paradigm OUS businesses to Companion Spine for approximately $19.2 million. The transaction, which includes $11 million in cash and $8.2 million in seller financing, aims to strengthen Xtant's focus on its core biologics business. The proceeds will be used to reduce debt and enhance liquidity.
Read more →XTNTXtant Medical Reports Third Quarter 2025 Financial Results
Xtant Medical Holdings, Inc. reported a 19% increase in total revenue for Q3 2025, reaching $33.3 million. The company achieved positive net income of $1.3 million and adjusted EBITDA of $4.5 million, reflecting significant improvements from the previous year. Xtant reiterated its full-year revenue guidance of $131-$135 million, indicating expected growth of 11%-15% over FY24.
Read more →XTNT▲ +7.5%on this newsshared move
Xtant Medical Announces Commercial Launch of CollagenX™
Xtant Medical has announced the commercial launch of CollagenX™, a bovine collagen particulate product aimed at enhancing surgical wound closure. This addition to their biologics portfolio is designed to promote healing and prevent complications such as dehiscence and infections. The company emphasizes its commitment to innovation and improving patient outcomes through this new product.
Read more →XTNT▼ -8.6%on this newsshared move
Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025
Xtant Medical Holdings, Inc. announced that it will release its third quarter financial results for the period ending September 30, 2025, on November 11, 2025. The announcement includes details for a conference call hosted by the CEO and CFO at 8:30 AM ET the same day. Investors can also access a replay of the call on the company's website following the live event.
Read more →XTNTTYLER LIPSCHULTZ
Mr. Tyler Lipschultz has been appointed to the Audit and Compensation Committees, bringing over 35 years of leadership experience in orthopaedics, spine, and biologics. He currently serves as President of LocateBio, Inc. and has held various senior roles in notable medical technology companies. His extensive background in the industry is expected to provide valuable insights to the Board.
Read more →XTNT▲ +6.2%on this newsshared move
Sean Browne
Sean Browne has been appointed as the Chief Executive Officer, bringing over 30 years of experience in the medical device and healthcare sectors. His previous roles include Chief Revenue Officer at CCS Medical and COO at The Kini Group. Browne's extensive background includes leadership positions at notable companies such as Integra LifeSciences and McKesson Corporation.
Read more →XTNT▲ +6.2%on this newsshared move
JOHN BAKEWELL
John K. Bakewell has been appointed as a director and chair of the audit committee. He brings a wealth of experience from his previous roles as CFO at several medical technology companies. His financial expertise and leadership in the industry will contribute significantly to the board's effectiveness.
Read more →XTNT▲ +6.2%on this newsshared move
JONN BEESON
Mr. Jonn Beeson serves as the Chair of the Compensation and Audit Committees. A partner at Jones Day, he has been practicing corporate law since 1996, specializing in mergers and acquisitions, corporate governance, and stockholder activism. His experience spans various industries, particularly in life sciences and medical devices.
Read more →XTNTABHINAV (ABI) JAIN
Abhinav Jain has been appointed to the Compensation Committee and Nominating and Corporate Governance Committee. He has a strong background in investment management and currently serves on the boards of two specialty pharmaceutical companies. His financial expertise is expected to add significant value to the Board.
Read more →XTNTSTAVROS G. VIZIRGIANAKIS
Stavros G. Vizirgianakis has been appointed as the Chair of the Board of Directors and Chair of the Corporate Governance and Nominating Committee at XTNT. With a notable background in the medical devices industry, he previously served as CEO of Misonix and co-founded Surgical Innovations. His extensive experience includes leadership roles at various medical companies.
Read more →XTNTScott Neils
Scott Neils has been appointed as Chief Financial Officer at Xtant Medical. With 15 years of experience in public accounting and corporate finance, he previously served as the Company's Controller. Neils has held senior positions at Baker Tilly and Grant Thornton, showcasing his expertise in managing finance and accounting functions.
Read more →XTNTMark Schallenberger
Mark Schallenberger has been appointed as the Chief Operating Officer of Xtant Medical. He brings a wealth of experience in orthobiologics, having previously served as COO at Surgenex LLC and held senior roles at DCI Donor Services Tissue Bank. Schallenberger's academic credentials include a Master's in Chemical Biology and a Bachelor's in Chemistry.
Read more →XTNTXtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Xtant Medical Holdings, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025. CEO Sean Browne and CFO Scott Neils will represent the company, with a presentation available on demand starting September 5. Investors can also schedule virtual one-on-one meetings with the management team.
Read more →XTNT▲ +14.1%on this news
Xtant Medical Reports Second Quarter 2025 Financial Results
Xtant Medical Holdings, Inc. reported its financial results for the second quarter of 2025, highlighting a total revenue of $35.4 million, which reflects an 18% increase compared to the previous year. The company achieved positive net income, adjusted EBITDA, and operating cash flow. Additionally, Xtant raised its revenue guidance for FY25 to a range of $131-$135 million, indicating expected growth of 11%-15% over FY24.
Read more →XTNT▲ +14.1%on this newsshared move
Xtant Medical Reports Second Quarter 2025 Financial Results Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance t
Xtant Medical reported strong financial results for Q2 2025, with total revenue of $35.4 million, up 18% from the previous year. The company demonstrated profitability with a net income of $3.6 million and adjusted EBITDA of $6.9 million. Xtant Medical increased its revenue guidance for FY25 to $131-$135 million, reflecting continued growth expectations. Additionally, plans to sell non-core spinal implants and businesses to Companion Spine aim to strengthen their focus and financial position.
Read more →XTNT▲ +9.8%on this newsshared move
Xtant Medical to Attend the CG 45th Annual Growth Conference
Xtant Medical Holdings, Inc. announced its participation in the CG 45th Annual Growth Conference on August 12, 2025. CEO Sean Browne and CFO Scott Neils will attend the event in Boston, MA, which includes 1x1 meetings and a presentation. The company focuses on surgical solutions for spinal, orthopedic, and wound care disorders.
Read more →XTNTXtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025
Xtant Medical Holdings, Inc. will announce its financial results for the second quarter of 2025 on August 12, 2025. A conference call will be hosted by CEO Sean Browne and CFO Scott Neils at 8:30 AM ET. The results will be available before trading begins, and a replay will be accessible on the company's website.
Read more →XTNTXtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine
Xtant Medical has announced definitive agreements for the sale of its Coflex® and CoFix® spinal implants, along with all international businesses, to Companion Spine. This transaction, valued at approximately $19.2 million, is expected to allow Xtant to concentrate more on its core operations while reducing debt and improving liquidity.
Read more →XTNTXtant Medical Announces Definitive Agreements for the Sale of its Coflex and CoFix Spinal Implants and All OUS Businesses to Companion Spine Transaction expected to facilitate enhanced focus on Xtant's core businesses To
Xtant Medical Holdings, Inc. has announced definitive agreements to sell its Coflex and CoFix spinal implants along with all international operations to Companion Spine for approximately $19.2 million. The deal, expected to close in Q3 2025, aims to enhance Xtant's focus on core orthobiologic businesses and improve its liquidity. Companion Spine plans to transition some Xtant staff to ensure continuity in the support of the sold product lines. This acquisition is set to position Companion Spine as a leader in posterior dynamic stabilization solutions.
Read more →XTNTXtant Medical Announces the Launch of OsteoFactor Pro™
Xtant Medical has launched OsteoFactor Pro™, an allogeneic growth factor solution aimed at accelerating bone repair. This product is characterized by a naturally derived formulation that enhances bone regeneration and integrates easily with various scaffolds. The introduction of OsteoFactor Pro™ marks Xtant's commitment to innovation in the orthobiologics field, enabling versatile treatment options for surgeons. It is now available through the company's distribution network across the United States.
Read more →XTNT▲ +14.7%on this news· ran to +27% by day 3
Xtant Medical Reports First Quarter 2025 Financial Results
Xtant Medical Holdings, Inc. reported a strong financial performance for the first quarter of 2025, with an 18% increase in revenue compared to the previous year. The company achieved positive net income and generated $1.3 million in operating cash flow. Additionally, Xtant raised its revenue guidance for 2025 to a range of $127 million to $131 million.
Read more →XTNTXtant Medical Reports First Quarter 2025 Financial Results Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131
Xtant Medical Holdings, Inc. reported a strong first quarter for 2025, with an 18% increase in revenue compared to the previous year. The company achieved positive net income and generated $1.3 million in operating cash flow, which supports future growth without needing external capital. Additionally, Xtant launched a new product, Trivium, showing promising early demand. The company has increased its full-year revenue guidance to between $127 million and $131 million, reflecting continued positive momentum.
Read more →XTNTXtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025
Xtant Medical Holdings, Inc. announced it will release its financial results for the first quarter of 2025 on May 12, 2025. The report will be made available after market close, followed by a conference call involving company executives to discuss the results. The mission of Xtant Medical revolves around improving patient outcomes in surgical solutions for spinal and orthopedic disorders.
Read more →XTNT▼ -6.8%on this news
Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance
Xtant Medical Holdings, Inc. announced the launch of Trivium™, an advanced demineralized bone matrix allograft designed for improved bone grafting procedures. The product features PureLoc™ Fiber Technology, which enhances structural integrity, handling, and biological activity, promoting effective tissue ingrowth. Trivium is now available through Xtant's distribution network, with the company expressing confidence in its potential to deliver reliable surgical outcomes. However, there are uncertainties regarding market acceptance and the need for further clinical validation of the product's performance.
Read more →XTNTXtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%
Xtant Medical Holdings, Inc. has announced a secondary private sale of existing shares by OrbiMed. Additionally, the company anticipates a revenue growth of 18% to 19% for the first quarter of 2025. This growth is attributed to a strategic shift towards higher-margin orthobiologics and the introduction of new products.
Read more →XTNTXtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19% Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Sh
Xtant Medical Holdings, Inc. has announced a secondary private sale of 73.1 million shares previously held by OrbiMed Advisors LLC, marking a strategic shift that enhances operational flexibility. The company anticipates a revenue growth of 18% to 19% for Q1 2025, driven by improvements in orthobiologics and licensing revenue. Key initial investors, including Nantahala Capital Management, are committed to supporting Xtant's vision for maximizing stockholder value. Upcoming product launches are expected to further expand Xtant's market presence beyond spinal solutions.
Read more →XTNTXtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Xtant Medical Holdings, Inc. reported a 28% revenue growth for the full year 2024. The company anticipates revenues between $126 million and $130 million for 2025 without requiring additional capital. This positive outlook reflects the company's strong performance in the medical technology sector.
Read more →XTNTXtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 Revenue Growth of 28% Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital
Xtant Medical Holdings, Inc. reported a 28% revenue increase for the full year 2024, totaling $117.3 million, and announced a revenue guidance of $126 to $130 million for 2025. The company has successfully reduced operating expenses by over $5 million annually and has initiated a new manufacturing and licensing agreement to support growth. However, the company reported a net loss of $16.4 million for 2024, a significant decline from 2023's profit, and gross margins decreased during the period. Despite these challenges, Xtant Medical is optimistic about its future trajectory.
Read more →XTNT▼ -13.3%on this news
Xtant Medical Reports Third Quarter 2024 Financial Results
Xtant Medical Holdings, Inc. reported a 12% growth in revenue for the third quarter of 2024. The company reaffirmed its full-year revenue guidance, expecting between $116 million and $120 million, which indicates a growth of 27% to 31%. This positive performance highlights the company's strong market position.
Read more →XTNTXtant Medical Reports Third Quarter 2024 Financial Results Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31%
Xtant Medical Holdings, Inc. reported third quarter financial results for 2024, revealing a 12% increase in revenue totaling $27.9 million. The company reaffirmed its full-year revenue guidance of $116 million to $120 million, reflecting a growth forecast of 27% to 31%. Although operational advances are noted, the company also reported a net loss of $5.0 million, contrasting with a profit in the same quarter last year, driven partly by significant prior-year gains. The company launched two new products and experienced a 36% revenue increase year-to-date, demonstrating a strong response to market demands in spinal disorder treatments.
Read more →XTNTXtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference
Xtant Medical Holdings, Inc. announced that CEO Sean Browne and CFO Scott Neils will attend the 15th Annual Craig-Hallum Alpha Select Conference. This participation underscores the company's focus on engaging with stakeholders in the medical technology sector, particularly in spinal disorder solutions.
Read more →XTNTXtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024
Xtant Medical Holdings, Inc. has announced the upcoming release of its financial results for the third quarter of 2024, which will occur on November 12, 2024. The company specializes in surgical solutions for spinal disorders, indicating a focus on a critical area of healthcare. This announcement reflects the company's commitment to keeping stakeholders informed.
Read more →XTNT▲ +5.3%on this news
Xtant Medical Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System
Xtant Medical Holdings, Inc. has announced the launch of the Cortera Posterior Fixation System. This new product is designed to streamline thoracolumbar fixation surgeries, enhancing the company's offerings in spinal disorder treatment. The launch reflects Xtant Medical's commitment to innovation in medical technology.
Read more →XTNT▲ +23.7%on this newsshared move
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus
Xtant Medical Holdings, Inc. has announced the launch of OsteoVive Plus, a viable bone matrix product. This addition enhances their existing product portfolio aimed at surgical solutions for spinal disorders. The launch reflects the company's commitment to innovation in the medical technology sector.
Read more →XTNT▼ -25.5%on this news
SURGALIGN HOLDINGS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited, in thousands, except share data)
Surgalign Holdings, Inc. reported its condensed consolidated balance sheets, highlighting a notable decline in both current assets and stockholders' equity. As of June 30, 2023, total current assets decreased to $39,346 thousand, a substantial drop from $56,711 thousand at the end of 2022. The company's operating loss improved but remains significant at $14,977 thousand, prompting concerns about its financial viability, as indicated by an accumulated deficit of $618,392 thousand. The report shows that total liabilities have notably exceeded total assets, posing challenges for future financial stability.
Read more →XTNTXtant Medical Announces $5.0 Million Private Placement BELGRADE, MT
Xtant Medical Holdings, Inc. has announced a private placement of $5.0 million by selling 7,812,500 shares at $0.64 each to an existing institutional investor. The funds will be used for working capital and other corporate needs. The placement will close on or around August 9, 2024, pending customary closing conditions. There are inherent risks related to this placement, including uncertainties about the company's future performance and reliance on external suppliers.
Read more →XTNTXtant Medical Reports Second Quarter 2024 Revenue Growth of 48%
Xtant Medical Holdings, Inc. reported a 48% revenue growth in its second quarter 2024 results, with revenues reaching $29.9 million. The company achieved a positive Adjusted EBITDA of $0.5 million, marking its fifth consecutive quarter of profitability in this metric. However, it also reported a net loss of $3.9 million, up from $2.2 million in the prior year, amid increasing expenses. Despite these challenges, Xtant Medical is optimistic about future growth, driven by new product launches and an expanding distributor network.
Read more →XTNT▼ -12.5%on this news
Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance
Xtant Medical Holdings, Inc. reported a significant revenue growth of 55% for the first quarter of 2024. The company has raised its revenue guidance for the full year to between $116 million and $120 million. This positive trend highlights the company's strong position in the surgical solutions market for spinal disorders.
Read more →XTNTXtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT
Xtant Medical Holdings, Inc. reported strong financial results for the first quarter of 2024, highlighting a revenue growth of 55% compared to the previous year. The company achieved an adjusted EBITDA of $0.1 million, marking a notable improvement from a loss in the prior year's quarter. Additionally, Xtant Medical has raised its revenue guidance for the full year 2024 to a range of $116 million to $120 million, which reflects an anticipated growth of 27% to 31%. Despite these positive results, the company cautioned about ongoing supply chain challenges and an increased net loss during the same period.
Read more →XTNTXtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024
Xtant Medical Holdings, Inc. has announced the release date for its financial results for the first quarter of 2024. The results will be disclosed on May 15, 2024, following the end of the quarter on March 31, 2024. This announcement reflects the company's ongoing operations and financial performance.
Read more →XTNTXtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
Xtant Medical has announced the commercial launch of SimpliGraft and SimpliMax, two new amniotic membrane allografts aimed at treating chronic and acute wounds. The products are manufactured in Belgrade, Montana, and will be marketed through a nationwide distribution network. This launch signifies Xtant's entry into the wound care market and reflects advancements in their bio-manufacturing capabilities.
Read more →XTNT▼ -12%on this news
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
Xtant Medical reported record revenues of $91.3 million for 2023, marking a 58% increase from the previous year. The company anticipates 2024 revenues between $112 million and $116 million, reflecting continued growth. Despite a net loss in Q4, the integration of new businesses and improved gross margins indicate a positive outlook for the company.
Read more →XTNTXtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024
Xtant Medical Holdings, Inc. will announce its financial results for Q4 and the full year 2023 on April 1, 2024. The announcement will be made before the market opens, followed by a conference call at 9:00 AM ET. This call will be led by the CEO and CFO, offering a platform for discussing the results.
Read more →XTNTXtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial
Xtant Medical Holdings has amended its revolving credit agreement with MidCap Financial, increasing the commitment from $8 million to $17 million. The company also secured an additional $10 million tranche for acquisitions. The maturity dates for the credit facility and term loan have been extended to March 1, 2029, and the interest rate on the term loan has been reduced.
Read more →XTNT▲ +6.3%on this news
Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference
Xtant Medical Holdings, Inc. will present at the TD Cowen 44th Annual Healthcare Conference on March 4, 2024. CEO Sean Browne will lead the presentation at 12:50 p.m. ET in Boston. A live webcast will be available, with a replay accessible for 90 days post-event. The company focuses on surgical solutions for spinal disorders.
Read more →XTNTXtant Medical to Participate in Upcoming Investor Conferences
Xtant Medical Holdings, Inc. has announced its participation in two upcoming investor conferences, the Canaccord Genuity 2024 Musculoskeletal Conference on February 12 and the BTIG Medtech Conference from February 13-14. The company aims to enhance investor engagement through live webcasts available on its website. This participation reflects Xtant's commitment to transparency and investor relations.
Read more →XTNTXtant Medical Announces Record Third Quarter Revenue of $25 Million
Xtant Medical Holdings, Inc. reported a record revenue of $25 million for the third quarter of 2023. The company has also raised its annual revenue guidance to between $88 million and $91 million. This positive financial performance highlights the company's growth in surgical solutions for spinal disorders.
Read more →XTNTXtant Medical Announces Record Third Quarter Revenue of $25 Million Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million BELGRADE, MT
Xtant Medical Holdings, Inc. announced a record third quarter revenue of $25 million, representing a 73% increase year-over-year. The company also raised its annual revenue guidance for 2023 to between $88 million and $91 million, driven by strong organic growth and contributions from recent acquisitions. The integration of Surgalign's hardware and biologics business has progressed smoothly and is expected to enhance operational efficiency. However, increased expenses and reliance on independent distributors raise some concerns regarding the company's financial stability moving forward.
Read more →XTNTXtant Medical to Issue Third Quarter 2023 Financial Results on November 9, 2023
Xtant Medical Holdings, Inc. has announced that it will release its financial results for the third quarter of 2023 on November 9, 2023. This release is part of the company's commitment to transparency and communication with its investors. The company specializes in surgical solutions for spinal disorders.
Read more →XTNTXtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical
Xtant Medical has acquired the nanOss production operations from RTI Surgical for $2 million, enhancing its manufacturing capabilities and control over the nanOss product line. This acquisition is expected to drive growth and improve cash flows. Xtant previously secured distribution rights and intellectual property related to nanOss, further solidifying its position in the orthobiologics market.
Read more →XTNTXtant Medical Highlights Growing Product Portfolio at NASS 2023
Xtant Medical Holdings, Inc. is set to exhibit its expanding range of orthobiologics and spinal fixation products at NASS 2023. The company emphasizes its commitment to providing advanced surgical solutions for spinal disorders. This event marks a significant opportunity for Xtant to showcase its innovations in the medical technology sector.
Read more →XTNTXtant Medical Completes Acquisition of Surgalign's Hardware and Biologics Business BELGRADE, MT
Xtant Medical has completed the acquisition of Surgalign's hardware and biologics business, which includes certain assets and liabilities. The all-cash transaction, amounting to $5 million, is expected to enhance Xtant's portfolio in orthobiologics and spinal fusion devices. Following this acquisition, the company has increased its revenue guidance for 2023. The firm plans to focus on integrating the newly acquired assets with its existing business to maximize potential benefits.
Read more →XTNT▲ +13.4%on this news
Xtant Medical Announces Second Quarter Revenue Growth of 32%
Xtant Medical Holdings, Inc. reported a 32% increase in revenue for the second quarter of 2023. The company has raised its annual revenue guidance to between $75 million and $77 million. This growth reflects Xtant's commitment to providing innovative surgical solutions for spinal disorders.
Read more →XTNT▲ +13.4%on this newsshared move
Xtant Medical Announces Second Quarter Revenue Growth of 32% Raises 2023 Annual Revenue Guidance to $75 Million - $77 Million BELGRADE, MT
Xtant Medical Holdings, Inc. reported a strong revenue growth of 32% for the second quarter of 2023, attributing this increase to successful sales from its core biologics and fixation products, as well as contributions from recently acquired devices. The company has raised its 2023 annual revenue guidance to between $75 million and $77 million, suggesting a positive outlook. However, net losses increased to $2.2 million, which may raise some concerns about future profitability amidst rising production costs.
Read more →XTNTXtant Medical Wins Auction for Surgalign’s Hardware and Biologics Business
Xtant Medical Holdings, Inc. has successfully acquired Surgalign's hardware and biologics business, a strategic move aimed at enhancing its spinal fusion devices portfolio. This acquisition is expected to strengthen Xtant's market position in the medical technology sector focused on surgical solutions for spinal disorders. The announcement was made on July 28, 2023.
Read more →XTNTXtant Medical Wins Auction for Surgalign's Hardware and Biologics Business Acquisition to Enhance Xtant's Growing Spinal Fusion Devices Portfolio BELGRADE, MT
Xtant Medical Holdings, Inc. has won the auction for Surgalign's hardware and biologics business, a significant addition to its spinal fusion devices portfolio. This acquisition, along with Xtant's recent acquisition of the Coflex product line, is expected to enhance their growth trajectory in the spinal sector. However, the deal is subject to approval from the Bankruptcy Court, with closing anticipated by early September 2023. The company’s CEO has expressed confidence in the benefits of this transaction, although it carries associated integration risks.
Read more →XTNTXtant Medical to Issue Second Quarter 2023 Financial Results on August 1, 2023
Xtant Medical Holdings, Inc. has announced the release date for its financial results for the second quarter of 2023, which will be on August 1, 2023. The company specializes in surgical solutions for spinal disorders. This announcement is part of their commitment to keeping stakeholders informed about their financial performance.
Read more →XTNTXtant Medical Appoints Lori Mitchell-Keller to Board of Directors BELGRADE, MT
Xtant Medical Holdings, Inc. has appointed Lori Mitchell-Keller to its Board of Directors as of May 16, 2023. Ms. Mitchell-Keller will also participate in the Compensation and Audit Committees. With over thirty years of experience in various industries including software and marketing, her role is seen as a vital addition to the company's growth strategy. The company highlights its promising trajectory in the orthobiologics and spine fixation market, particularly after acquiring the Coflex product line.
Read more →XTNT▲ +6.6%on this news
Xtant Medical Announces First Quarter 2023 Revenue Growth of 38% and Full Year 2023 Revenue Guidance Initiates Annual Revenue Guidance of $73 Million - $75 Million in Full Year 2023 BELGRADE, MT
Xtant Medical Holdings, Inc. reported a significant revenue growth of 38% for the first quarter of 2023, reaching $17.9 million compared to $13.0 million in the same period last year. This growth was aided by an organic increase of 29% and contributions from the recent acquisition of the Coflex and CoFix product lines. The company has set its revenue guidance for the full year of 2023 at $73 million to $75 million, reflecting anticipated annual growth of 26% to 29%. However, the company also reported a net loss of $2.1 million, attributed to increased expenses despite this positive revenue momentum.
Read more →XTNTXtant Medical Announces Fourth Quarter and Full Year 2022 Financial Results BELGRADE, MT
Xtant Medical Holdings, Inc. has reported its financial results for the fourth quarter and full year 2022, showing a revenue increase of 9% in Q4. The company celebrated the acquisition of the Coflex product line, which is expected to bolster its offerings in spinal solutions. Despite revenue growth, a net loss of $8.5 million for the year has been reported, reflecting increased expenses and production costs. The company feels well-positioned for future success driven by strong demand and operational improvements.
Read more →XTNT▲ +7.7%on this news· ran to +30% by day 1
Xtant Medical Acquires Coflex Product Line from Surgalign for $17 Million Expands Xtant's Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device Strengthens Surgalign's Balance Sheet as it Embar
Xtant Medical has successfully acquired the Coflex and Cofix product lines from Surgalign for $17 million. This acquisition bolsters Xtant's offerings in the interlaminar stabilization market, specifically targeting lumbar spinal stenosis patients. The Coflex device is the only FDA PMA-approved implant for this condition and is already implanted in over 200,000 patients worldwide. Xtant anticipates that these products will contribute approximately $14 million in annual revenue, enhancing its potential for achieving profitability.
Read more →XTNTXtant Medical Appoints Mark Schallenberger as Chief Operations Officer BELGRADE, MT
Xtant Medical Holdings, Inc. has appointed Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. Schallenberger, who has over 12 years of experience in orthobiologics, will oversee the modernization of production processes and the development of new product lines. Sean Browne, the company's CEO, expressed optimism about Schallenberger's contributions, highlighting the company's commitment to growth and operational efficiencies.
Read more →XTNTXtant Medical Announces Third Quarter 2022 Financial Results BELGRADE, MT
Medical Announces Third Quarter 2022 Financial Results MT, November 3, 2022 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating resu
Read more →XTNTXtant Medical Announces Closing of Second Tranche of $9.75 Million Private Investment BELGRADE, MT
Medical Announces Closing of Second Tranche of $9.75 Million Private Investment MT, October 11, 2022 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced th
Read more →XTNTXtant Medical Announces Closing of First Tranche of $9.75 Million Private Investment BELGRADE, MT
Medical Announces Closing of First Tranche of $9.75 Million Private Investment MT, August 31, 2022 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the
Read more →XTNT▲ +6.8%on this news
Xtant Medical Announces $9.75 Million Private Investment Upon completion of first closing, Stavros Vizirgianakis to become Non-Executive Chairman BELGRADE, MT
Medical Announces $9.75 Million Private Investment completion of first closing, Stavros Vizirgianakis to become Non-Executive Chairman MT, August 24, 2022 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions fo
Read more →XTNTXtant Medical Announces Second Quarter 2022 Financial Results BELGRADE, MT
Medical Announces Second Quarter 2022 Financial Results MT, August 4, 2022 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating resul
Read more →XTNTXtant Medical Announces First Quarter 2022 Financial Results BELGRADE, MT
Medical Announces First Quarter 2022 Financial Results MT, May 5, 2022 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results f
Read more →XTNT▼ -14.9%on this news· ran to -25% by day 3
Xtant Medical Announces Fourth Quarter and Full Year 2021 Financial Results BELGRADE, MT
Medical Announces Fourth Quarter and Full Year 2021 Financial Results MT, March 8, 2022 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and op
Read more →XTNT▲ +9.4%on this news
Xtant Medical Appoints Scott Neils Interim Chief Financial Officer BELGRADE, MT
Medical Appoints Scott Neils Interim Chief Financial Officer MT, January 3, 2022 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Sco
Read more →XTNTXtant Medical Announces Third Quarter 2021 Financial Results BELGRADE, MT
Medical Announces Third Quarter 2021 Financial Results MT, November 12, 2021 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating res
Read more →XTNTXtant Medical Announces Second Quarter 2021 Financial Results BELGRADE, MT
Medical Announces Second Quarter 2021 Financial Results MT, August 5, 2021 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating resul
Read more →XTNTXtant Medical Announces First Quarter 2021 Financial Results BELGRADE, MT
Medical Announces First Quarter 2021 Financial Results MT, May 11, 2021 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results
Read more →XTNTXtant Medical Announces Fourth Quarter and Full Year 2020 Financial Results BELGRADE, MT
Medical Announces Fourth Quarter and Full Year 2020 Financial Results MT, February 24, 2021 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial an
Read more →XTNTXTANT MEDICAL ANNOUNCES $20
MEDICAL ANNOUNCES $20 MILLION PRIVATE PLACEMENT MT., February 22, 2021 - Xtant Medical Holdings, Inc. (NYSE American: XTNT) (the Company), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered int
Read more →XTNTXtant Medical Announces Expiration of Rights Offering BELGRADE, MT
Medical Announces Expiration of Rights Offering MT, December 7, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the subscription period for i
Read more →XTNTXtant Medical Announces Third Quarter 2020 Financial Results BELGRADE, MT
Medical Announces Third Quarter 2020 Financial Results MT, October 29, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating resu
Read more →XTNTXtant Medical Announces Record Date and Other Key Dates for Proposed $15 Million Rights Offering BELGRADE, MT
Medical Announces Record Date and Other Key Dates for $15 Million Rights Offering MT, October 22, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced
Read more →XTNTXtant Medical Regains Compliance with NYSE American Continued Listing Standards BELGRADE, MT
Medical Regains Compliance with NYSE American Continued Listing Standards MT, October 6, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it r
Read more →XTNTXtant Medical Announces Closing of Debt Restructuring BELGRADE, MT
Medical Announces Closing of Debt Restructuring MT, October 1, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has completed its previousl
Read more →XTNTXtant Medical Announces Debt Restructuring BELGRADE, MT
Medical Announces Debt Restructuring MT, August 10, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has entered into a Restructuring and E
Read more →XTNTXtant Medical Announces Second Quarter 2020 Financial Results BELGRADE, MT
Medical Announces Second Quarter 2020 Financial Results MT, August 3, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating resul
Read more →XTNTXtant Medical Announces First Quarter 2020 Financial Results BELGRADE, MT
Medical Announces First Quarter 2020 Financial Results MT, May 7, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results f
Read more →XTNTXtant Medical Announces Fourth Quarter and Full Year 2019 Financial Results BELGRADE, MT
Medical Announces Fourth Quarter and Full Year 2019 Financial Results MT, March 5, 2020 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and op
Read more →XTNTXtant Medical Announces Third Quarter 2019 Financial Results BELGRADE, MT
Medical Announces Third Quarter 2019 Financial Results MT, November 7, 2019 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating resu
Read more →XTNTXtant Medical Names Sean Browne President and Chief Executive Officer BELGRADE, MT
Medical Names Sean Browne President and Chief Executive Officer MT, October 7, 2019 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of
Read more →XTNTXtant Medical Announces Second Quarter 2019 Financial Results BELGRADE, MT
Medical Announces Second Quarter 2019 Financial Results MT, August 8, 2019 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating resul
Read more →XTNTXtant Medical Announces NYSE American Acceptance of Plan to Regain Compliance with Continued Listing Standards BELGRADE, MT
Medical Announces NYSE American Acceptance of Plan to Regain Compliance with Continued Listing Standards MT, May 28, 2019 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorder
Read more →XTNTXtant Medical Announces First Quarter 2019 Financial Results BELGRADE, MT
Medical Announces First Quarter 2019 Financial Results MT, May 15, 2019 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results
Read more →XTNTXtant Medical Receives Noncompliance Notice from NYSE American BELGRADE, MT
Medical Receives Noncompliance Notice from NYSE American MT, April 5, 2019 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced receipt of notification from
Read more →XTNTXtant Medical Announces Fourth Quarter and 2018 Financial Results BELGRADE, MT
Medical Announces Fourth Quarter and 2018 Financial Results MT, April 1, 2019 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating re
Read more →XTNTXtant Medical Announces Appointment of New Senior Sales Leaders
BELGRADE, MT, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the recent additions of five senior sales executives: Dana
Read more →XTNTXtant Medical Announces Appointment of Chief Operations Officer
BELGRADE, MT, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the appointment of Ronald Berlin as Vice President & Chief
Read more →XTNTXtant Medical Announces Third Quarter 2018 Financial Results BELGRADE, MT
Medical Announces Third Quarter 2018 Financial Results MT, November 14, 2018 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the third qua
Read more →XTNTXtant Medical to Issue Third Quarter 2018 Results on November 14, 2018
BELGRADE, MT, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarter and year to date ended
Read more →XTNTXtant Medical Announces Appointment of Interim CEO BELGRADE, MT (
Medical Announces Appointment of Interim CEO MT (October 15, 2018) - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the appointment of Michael Mainelli
Read more →XTNTXtant Medical Announces Amendments to Credit Facility and Issuance of Warrants BELGRADE, MT
Medical Announces Amendments to Credit Facility Issuance of Warrants MT, Sept. 17, 2018 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine products and medical devices, today announced it has execute
Read more →XTNTXtant Medical Announces Appointment of Chief Financial Officer BELGRADE, MT, Aug XX, 2018 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine p
Medical Announces Appointment of Chief Financial Officer MT, Aug XX, 2018 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine products and medical devices, today announced the appointment of Kathie Len
Read more →XTNTXtant Medical Announces Second Quarter 2018 Financial Results BELGRADE, MT
Medical Announces Second Quarter 2018 Financial Results MT, Aug 7, 2018 - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the second quarter
Read more →XTNTXtant Medical to Issue Second Quarter 2018 Results on August 7, 2018
BELGRADE, MT, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announces that it will release its financial results for the quarter ended June 30, 2018, a
Read more →XTNTXtant Medical Appoints Kevin Brandt as Chief Commercial Officer BELGRADE, MT
Medical Appoints Kevin Brandt as Chief Commercial Officer MT, July 10, 2018 (ACCESSWIRE) - Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Kevin Brandt to th
Read more →XTNTXtant Medical Holdings, Inc. Announces Expiration of Rights Offering BELGRADE, MT
Medical Holdings, Inc. Announces Expiration of Rights Offering MT, June 19, 2018 (GLOBE NEWSWIRE) - XtantTM Medical Holdings, Inc. (NYSE American: XTNT) announces that the subscription period for its previously announced rights offering (the "Offering") of shares of the Company
Read more →XTNTXtant Medical Receives FDA 510(k) Clearance for InTice -C Porous Titanium Cervical Interbody System BELGRADE, MT.
Xtant Medical Receives FDA 510(k) Clearance for InTice -C Porous Titanium Cervical Interbody System BELGRADE, MT., May. 21, 2018 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces
Read more →XTNTXtant Medical Holdings, Inc. Announces Record Date for Proposed Rights Offering BELGRADE, MT / ACCESSWIRE /
Xtant Medical Holdings, Inc. Announces Record Date for Proposed Rights Offering BELGRADE, MT / ACCESSWIRE / April 17, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced today that it has set April 27, 2018 as the record date for a proposed rights offering of i
Read more →XTNTXtant Announces Fourth Quarter and Year End 2017 Financial Results
Fourth Quarter and Year End 2017 Financial Results Mont., April 2, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today reported its financial results for the period
Read more →XTNTXtant Medical to Issue Fourth Quarter and Full Year 2017 Financial Results Monday, April 2
Xtant Medical to Issue Fourth Quarter and Full Year 2017 Financial Results Monday, April 2 BELGRADE, Mont., March 27, 2018 (ACCESSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, toda
Read more →XTNTXtant Medical Announces Compliance with NYSE American
Reports Pro Forma Stockholders’ Equity of approximately $47.4M as of 2/15/18 Xtant has regained compliance with the NYSE American listing standards BELGRADE, Mont., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development
Read more →XTNTXtant Medical Announces Exchange of Outstanding Convertible Notes and Closing of Private Placement Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share. $6.8
Medical Announces Exchange of Outstanding Convertible Notes and Closing of Private Placement Mont., February 14, 2018 (GLOBE NEWSWIRE) - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today
Read more →XTNTXtant Medical Announces Results of Special Meeting of Stockholders Approval of the issuance of new shares of common stock, as required by the NYSE American. Approval of an amendment to its certificate of incorporation, e
Xtant Medical Announces Results of Special Meeting of Stockholders BELGRADE, Mont., February 13, 2018 (GLOBE NEWSWIRE) - Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the r
Read more →XTNTXtant Medical Enters into Restructuring and Exchange Agreement with All Holders of Outstanding Convertible Notes Conversion of $1.627M (plus interest) of convertible notes into common stock Exchange of $70.238M (plus int
Xtant Medical Enters into Restructuring and Exchange Agreement with All Holders of Outstanding Convertible Notes BELGRADE, Mont., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products
Read more →XTNTXtant Medical Reports Third Quarter 2017 Financial Results Company restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Reported third quarter 2017 revenue of $19.8 million
Medical Reports Third Quarter 2017 Financial Results restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Mont., November 21, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development
Read more →XTNTXtant Medical Postpones Release of Third Quarter 2017 Financial Results
Medical Postpones Release of Third Quarter 2017 Financial Results Mont., November 9, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed th
Read more →XTNTXtant Medical Enters into a Distribution Agreement with curasan, Inc. Bringing Matriform to Market
Medical Enters into a Distribution Agreement with curasan, Inc. Bringing Matriform to Market Mont., Nov. 1, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today annou
Read more →XTNTXtant Medical to Announce Third Quarter 2017 Results on Wednesday, November 8th
Xtant Medical to Announce Third Quarter 2017 Results on Wednesday, November 8th BELGRADE, Mont., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today annou
Read more →XTNTXtant Medical to Feature Product Portfolio at the 2017 North American Spine Society Annual Meeting
Feature Product Portfolio at the 2017 North American Spine Society Annual Meeting BELGRADE, Mont., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced
Read more →XTNTXtant Medical Announces Consolidation of Fixation Operations to Montana and Closure of Dayton Facility Expected approximate $2 million savings when implemented BELGRADE, Mont., Oct. 06 2017 (GLOBE NEWSWIRE) -- Xtant Medi
Xtant Medical Announces Consolidation of Fixation Operations to Montana and Closure of Dayton Facility approximate $2 million savings when implemented Oct. 06 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerativ
Read more →XTNTXtant Medical Receives 510k Clearance for Expanded Indications of Irix-A
Xtant Medical Receives 510k Clearance for Expanded Indications of Irix-A BELGRADE, Mont., Sep. 12, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that
Read more →XTNTXtant Medical Reports Second Quarter 2017 Financial Results Company Continues to Take Steps During Restructuring to Build for Future Growth
Xtant Medical Reports Second Quarter 2017 Financial Results Company Continues to Take Steps During Restructuring to Build Mont., August 9, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products
Read more →XTNTXtant Medical Receives FDA Clearance for Calix-C Cervical Interbody Line Extension and Expanded Indications
Xtant Medical Receives FDA Clearance for Calix-C Cervical Interbody Line Extension and Expanded Indications BELGRADE, Mont., August 9, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and
Read more →XTNTXtant Medical Joins the 2018 Donate Life Rose Parade Float to Highlight the Power of Organ, Eye, and Tissue Donation
BELGRADE, Mont., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, is proud to announce its sponsorship of the 2018 Donate Life float at the January 1 Rose Parade
Read more →XTNTXtant Medical to Announce Second Quarter 2017 Results on August 9th, 2017 BELGRADE, MT
to Announce Second Quarter 2017 Results on August 9th, 2017 24, 2017 -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the second qu
Read more →XTNTXtant Medical Announces Rescheduling of Annual Meeting
Xtant Medical Announces Rescheduling of Annual BELGRADE, Mont., May 26, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its board of directors has res
Read more →XTNTXtant Medical Enters into Licensing Agreement for Sites Medical's OsteoSync Ti Technology
Xtant Medical Enters into Licensing Agreement for Sites Medical's OsteoSync Ti Technology BELGRADE, Mont., May 16, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domes
Read more →XTNTXtant Medical Announces OrbiMed Financing and Engagement of Aurora Management Partners
Xtant Medical Announces OrbiMed Financing and Engagement of Aurora Management Partners May 12, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has enter
Read more →XTNTXtant Medical Reports First Quarter Revenue of $22.1 million, 5% Growth Compared to the Prior Year Period First Quarter 2017 Highlights: Consolidated total revenue increased 5.3% to $22.1 million compared to first quarte
Xtant Medical Reports First Quarter Revenue of $22.1 million, 5% Growth Compared to the Prior Year Period First Quarter 2017 Highlights: Consolidated total revenue increased 5.3% to $22.1 million compared to first quarter 2016 revenue of $21.0 million Consolidated gross pr
Read more →XTNTXtant Medical Sets Annual Meeting and Record Dates
Xtant Medical Sets Annual Meeting and Record BELGRADE, Mont., May 5, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, has established a record date for its 2017 annual meet
Read more →XTNTXtant Medical Announces Release of First Quarter 2017 Results on
Xtant Medical Announces Release of First Quarter 2017 Results BELGRADE, Mont., May 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it will release its f
Read more →XTNTXtant Medical Recognized as Montana Ambassador Business of the Year
Recognized as Montana Ambassador Business of the Year Mont., April. 25, 2017 (GLOBE NEWSWIRE) - Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced
Read more →XTNTXtant™ Medical Receives Going Concern Opinion
BELGRADE, Mont., April 05, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended
Read more →XTNTXtant Medical Receives Going Concern Opinion Belgrade, MT
Medical Receives Going Concern Opinion Belgrade, MT, April 05, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that as previously disclosed in its Annual R
Read more →XTNTXtant Medical Reports Record Fourth Quarter Revenue of $24.5 million, 10% Growth Compared to Prior Year Period See footnote about the use of pro forma financial information Fourth Quarter 2016 Highlights: Consolidated to
Xtant Medical Reports Record Fourth Quarter Revenue of $24.5 million, 10% Growth Compared to Prior Year Period See footnote about the use of pro forma financial information Fourth Quarter 2016 Highlights: - Consolidated total revenue increased 9.9% to a record $24.5 million
Read more →XTNTXtant Medical to announce Fourth Quarter and Full Year 2016 Results on March 9th, 2017 BELGRADE, MT
Xtant Medical to announce Fourth Quarter and Full Year 2016 Results on March 9th, 2017 BELGRADE, MT, March 1, 2017 -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will
Read more →XTNTXtant Medical Announces Appointment of Carl O'Connell to Permanent
Medical Announces Appointment of Carl O'Connell to Permanent CEO February 22, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O'Conn
Read more →XTNTXtant Medical CEO Dan Goldberger announces resignation
BELGRADE, Mont., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that on January 21, 2017, Dan Goldberger resign
Read more →XTNTBELGRADE, Mont.
BELGRADE, Mont., Jan. 23, 2017 (GLOBE NEWSWIRE) - Xtant Medical Holdings, Inc. today announced that on January 21, 2017, Dan Goldberger resigned as Chief Executive Officer and as a Director of the Company and its subsidiaries to pursue other interests. Current President Carl O'
Read more →XTNTXTNT Announces Issuance of PIK Notes
XTNT Announces Issuance of PIK Notes BELGRADE, Mont., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the
Read more →XTNTXTNT Announces Closing of Registered Direct Offering
XTNT Announces Closing of Registered BELGRADE, Mont., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the
Read more →XTNTXTNT Announces Registered Direct Offering
XTNT Announces Registered Direct Offering BELGRADE, Mont., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT),a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced
Read more →XTNTXTNT Announces Preliminary Fourth Quarter and Full Year 2016 Revenue & Adjusted EBITDA Record Fourth Quarter 2016 Revenue is estimated to be at least $24.5 million which represents 10.0% year on year growth Full Year 201
XTNT Announces Preliminary Fourth Quarter and Full Year 2016 Revenue & Adjusted EBITDA BELGRADE, Mont., Jan. 11, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic
Read more →XTNTXtant Medical Receives FDA Clearance for the Xsert Lumbar Expandable Interbody System
Xtant Medical Receives FDA Clearance for the Xsert Lumbar Expandable Interbody System BELGRADE, Mont., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today annou
Read more →XTNTXtant Medical Closes Rights Offering for Gross Proceeds of $3.8 Million
Xtant Medical Closes Rights Offering for Gross Proceeds of $3.8 Million BELGRADE, Mont., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and internatio
Read more →XTNTXtant Medical Announces Expiration of Rights Offering and Estimated Gross Proceeds of $3.8 Million
BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that the subscription period for its previously
Read more →XTNTXtant Medical Receives FDA Clearance to Use Allografts in the Stand-Alone Irix-C Cervical Cage
Xtant Medical Receives FDA Clearance to Use Allografts in the Stand-Alone Irix-C Cervical Cage BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, to
Read more →XTNTXtant Medical Announces First Surgical Cases of Xspan™ Laminoplasty Fixation System
BELGRADE, Mont., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical cases of the Xspan Laminoplasty Fixation System. The first two c
Read more →XTNTXtant Medical Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period and Final Subscription Price
Xtant Medical Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period and Final Subscription Price BELGRADE, Mont., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketi
Read more →XTNTXtant Medical Announces Adjustment to Subscription Price of Rights Offering
Xtant Medical Announces Adjustment to Subscription Price BELGRADE, Mont., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, ann
Read more →XTNTXtant Medical Holdings Reports Record Third Quarter 2016 Results *See footnote about the use of pro forma financial information Third Quarter 2016 Highlights: Company revenue increased 10.5% to $23.1 million, as compared
Xtant Medical Holdings Reports Record Third Quarter 2016 Results *See footnote about the use of pro forma financial information Third Quarter 2016 Highlights: - Company revenue increased 10.5% to $23.1 million, as compared to pro forma revenue of $20.9 million in third quar
Read more →XTNTXtant Medical Receives Approval of Compliance Plan from
Xtant Medical Receives Approval of Compliance Plan BELGRADE, Mont., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today ann
Read more →XTNTXtant Medical Announces Commencement of Subscription Period for Previously Announced Rights Offering
BELGRADE, Mont., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that it has commenced the subscription period f
Read more →XTNTXtant Medical Reminds Shareholders That Rights Offering Ownership Day is Tuesday
Xtant Medical Reminds Shareholders That Rights Offering Ownership Day is Tuesday, October 18, 2016 at 4:00 PM ET BELGRADE, Mont., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthope
Read more →XTNTXtant Medical Holdings, Inc. to Report Third Quarter 2016 Financial Results on November 7, 2016
BELGRADE, Mont., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended September 30, 2016,
Read more →XTNTXtant Medical Pre-Announces Record Third Quarter 2016 Revenue *See footnote about the use of pro forma financial information o Record Third Quarter 2016 Revenue in the range of $23.0 million to $23.3 million o Third Quar
Xtant Medical Pre-Announces Record Third Quarter 2016 Revenue *See footnote about the use of pro forma financial BELGRADE, Mont., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and
Read more →XTNTXtant Medical Announces the Appointment of Carl O'Connell as President Belgrade, MT
Xtant Medical Announces the Appointment of Carl O'Connell as President Belgrade, MT, October 6, 2016 - Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O'C
Read more →XTNTXtant Medical Announces Key Dates Related to Previously Announced Rights Offering
BELGRADE, Mont., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today provided an informational update to stockholders and conv
Read more →XTNTXtant Medical Files S-1 Registration Statement for Rights Offering to Shareholders
Medical Files S-1 Registration Statement for Rights Offering to Shareholders Mont., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international ma
Read more →XTNTXtant Medical Receives Non Compliance Notice from
Xtant Medical Receives Non Compliance Notice from NYSE MKT BELGRADE, Mont., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets,
Read more →XTNTXtant Medical Receives Non Compliance Notice from NYSE MKT
BELGRADE, Mont., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that the NYSE MKT LLC (the "Exchange") notified
Read more →XTNTXtant Medical Expands AR Credit Facility with Silicon Valley Bank Expanded credit facility to provide additional liquidity for future growth
Medical Expands AR Credit Facility with Silicon Valley Bank Expanded credit facility to provide additional liquidity for future growth BELGRADE, Mont., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing a
Read more →XTNTXtant Medical Reports Second Quarter 2016 Results *See footnote about the use of pro forma financial information Second Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 5.6% to
Xtant Medical Reports Second Quarter 2016 Results *See footnote about the use of pro forma financial Second Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 5.6% to $20.9 million compared to core pro forma recurring revenue of $19.8
Read more →XTNTXtant™ Medical Reports Second Quarter 2016 Results
*See footnote about the use of pro forma financial information Second Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 5.6% to $20.9 million compared to core pro forma recurring revenue of $19.8 million in second quarter 2015 Gross pr
Read more →XTNTXtant Medical Announces the Operations Expansion of Montana's Tissue Processing Rooms Belgrade, MT
Xtant Medical Announces the Operations Expansion of Montana's Tissue Processing Rooms Belgrade, MT, July 26, 2016 - Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the expansion
Read more →XTNTXtant Medical Pre-Announces Second Quarter 2016 Revenue and EBITDA Second Quarter 2016 Revenue in the range of $21.45 million to $21.65 million Core recurring revenue to increase 5.6% to 6.6% over the same period last ye
Xtant Medical Pre-Announces Second Quarter 2016 Revenue and EBITDA BELGRADE, Mont., July 20, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, has preannounced that its second
Read more →XTNTXtant Medical Holdings, Inc. to Report Second Quarter 2016 Financial Results on August 1, 2016
BELGRADE, Mont., July 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended June 30th 2016, at the c
Read more →XTNTXtant Medical Announces Changes to Its Executive Management and Board of Directors
Announces Changes to Its Executive Management and Board of Directors BELGRADE, Mont., June 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointm
Read more →XTNTXtant Medical and Pinnacle Spine Group Announce Distribution Agreement, Expanding the Availability of Innovative InFill Lateral Fusion System
BELGRADE, Mont. and DALLAS, June 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices and Pinnacle Spine Group, LLC, a developer of innovative spinal fusion solutions, today an
Read more →XTNTXtant Medical Completes New Credit Facility Project: XTNT: SVB Facility PR - Xtant Medical Version: 7 - Updated on May 26 2016 at 15:08 by Molly Mason Xtant Medical Completes New Accounts Receivable Revolver Credit Facil
Completes New Credit Project: XTNT: SVB Facility PR - Xtant Version: 7 - Updated on May 26 2016 at 15:08 by Molly Mason Xtant Medical Completes New Accounts Receivable Revolver Credit Facility with Silicon Valley Bank facility provides additional working capital to continue
Read more →XTNTXtant Medical Completes New Accounts Receivable Revolver Credit Facility with Silicon Valley Bank
New facility provides additional working capital to continue Company market expansion plans BELGRADE, Mont., May 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domesti
Read more →XTNTXtant Medical to Present at Investor Conferences
BELGRADE, Mont., May 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced
Read more →XTNTXtant™ Medical Announces the FDA Clearance for the Posterior Cervical Screw Indication on Certex Spinal Fixation System
BELGRADE, Mont., May 12, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced FDA clearance for the posterior cervical screw indication on the Certex® Spinal Fixat
Read more →XTNTXtant™ Medical Reports First Quarter 2016 Results
See footnote about the use of pro forma financial information First Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 6.8% to $20.5 million compared to core pro forma recurring revenue of $19.2 million in first quarter 2015 Gross profi
Read more →XTNTXtant Medical Holdings, Inc. to Report First Quarter 2016 Financial Results on May 4, 2016
BELGRADE, Mont., April 27, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended March 31st, 2016, a
Read more →XTNTXtant Medical Announces Montana Department of Commerce Grant Awards
BELGRADE, Mont., April 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the awarding of two grants from the Montana Department of Commerce totaling $155,00
Read more →XTNTXtant Medical Pre-Announces First Quarter 2016 Revenue Core recurring revenue to increase 7% to 8% over first quarter 2015 The Company reiterates full-year 2016 revenue guidance of $94 million to $99 million and EBITDA g
Xtant Medical Pre-Announces First Quarter 2016 Revenue Core recurring revenue to increase 7% to 8% over first quarter 2015 The Company reiterates full-year 2016 revenue guidance of $94 million to $99 million and EBITDA guidance of $4.3 million to $6.3 million April 19, 2016
Read more →XTNTXtant Medical Announces FDA Clearance of the Xspan Laminoplasty Fixation System
Xtant Medical Announces FDA Clearance of the Xspan Laminoplasty BELGRADE, Mont., March 29, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly
Read more →XTNTXtant Medical Announces Distribution Agreement with Vivex Biomedical Bringing OsteoVive , a Cellular Allograft, to Market
Xtant Medical Announces Distribution Agreement with Vivex Biomedical Bringing OsteoVive , a Cellular Allograft, to Market BELGRADE, Mont., March 24, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products
Read more →XTNTXtant Medical Reports Record $22.3 Million Revenue and 14.1% Growth for the Fourth Quarter 2015 See footnote about the use of pro forma financial information Fourth Quarter 2015 Highlights: Consolidated total revenue inc
Medical Reports Record $22.3 Million Revenue and 14.1% Growth for the Fourth Quarter 2015 See footnote about the use of pro forma financial Consolidated total revenue increased 14.1% to a record $22.3 million compared to pro forma fourth quarter 2014 revenue of $19.5 million
Read more →XTNTXtant Medical Holdings, Inc. to Report Fourth Quarter 2015 Financial Results on March 15, 2016
BELGRADE, Mont., March 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended December 31st, 2015
Read more →XTNTXtant Medical Receives CE Mark for its Aranax Cervical Plating System and Irix-A Stand Alone Anterior Lumbar Interbody Fusion Device
Xtant Medical Receives CE Mark for its Aranax Cervical Plating System and Irix-A Stand Alone Anterior Lumbar Interbody Fusion Device BELGRADE, Mont., March 3, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative me
Read more →XTNTXtant Medical to Present at the Canaccord Genuity 2016 Musculoskeletal Conference
Xtant Medical to Present at the Canaccord Genuity 2016 Musculoskeletal Conference BELGRADE, Mont., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading rege
Read more →XTNTXtant Medical to Present at the Source Capital 2016 Disruptive Growth & Healthcare Conference
Xtant Medical to Present at the Source Capital 2016 Disruptive Growth & Healthcare Conference BELGRADE, Mont., Feb. 3, 2016 (GLOBE NEWSWIRE) - Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-le
Read more →XTNTXtant Medical Holdings, Inc. Reports Preliminary Fourth Quarter 2015 Financial Results BELGRADE, MT
Xtant Medical Holdings, Inc. Reports Preliminary Fourth Quarter 2015 Financial Results MT, January 12, 2016 -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced preliminary results
Read more →XTNTXtant Medical Announces First Surgical Procedure with the Aranax Cervical Plating System Belgrade, MT
Announces First Surgical Procedure with the Aranax Cervical Plating System Belgrade, MT, December 15, 2015 - Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical pro
Read more →XTNTXtant Medical Announces First Surgical Case of Atrix-C Cervical Allograft Interbody Spacer Belgrade, MT
Xtant Medical Announces First Surgical Case of Atrix-C Cervical Allograft Interbody Spacer Belgrade, MT, December 9, 2015 - Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the fi
Read more →XTNTXtant Medical Announces the Global Launch for the Certex OCT Spinal Fixation System BELGRADE, MT
Announces the Global Launch for the Certex OCT Spinal Fixation System MT, December 8, 2015 - Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spi
Read more →XTNTXtant™ Medical To Present at ICV Manhattan Conference
BELGRADE, Mont., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative medicine products and medical devices, today announced that its Chief Financial O
Read more →XTNTXtant Medical To Present at ICV Manhattan BELGRADE, Mont., DEC. 3, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of cl
Xtant Medical To Present at ICV Manhattan BELGRADE, Mont., DEC. 3, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative medicine products and medical de
Read more →XTNTXtant Medical and Montana State University Develop Custom 3D Printer for Prototyping Reconstructive Implants
Medical and Montana State University Develop Custom 3D Printer for Prototyping Reconstructive Implants BELGRADE, Mont., December 2, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical
Read more →XTNTXtant Medical Receives Clearance of Expanded Indication for Ilium Fixation and Deformity
Medical Receives Clearance of Expanded Indication for Ilium Fixation and Deformity Mont., Dec. 01, 2015 -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned sub
Read more →XTNTXtant Medical To Present at the 8th Annual LD Micro Conference
Medical To Present at the 8th Annual LD Micro Conference Mont., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative medicine products and medic
Read more →XTNTXtant Medical Holdings, Inc. Reports Third Quarter 2015 Results Third Quarter 2015 Consolidated Pro Forma Highlights: Consolidated pro forma revenue increased 6.5% to $20.9 million from $19.6 million in the third quarter
Medical Holdings, Inc. Reports Third Quarter 2015 Results Third Quarter 2015 Consolidated Pro Forma Nov. 11, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of class-leading regenerative medicine products and medical devices,
Read more →XTNTXtant Medical Holdings, Inc. to Report Third Quarter 2015 Financial Results on
Xtant Medical Holdings, Inc. to Report Third Quarter 2015 Financial Results on November 11, 2015 BELGRADE, MT, November 2, 2015 -- Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced
Read more →XTNTXtant Medical Announces First Surgical Use of OsteoSelect PLUS DBM Putty
Xtant Medical Announces First Surgical Use of OsteoSelect BELGRADE, Mont., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical impl
Read more →XTNTXtant Medical Holdings, Inc. to Report Third Quarter 2015 Financial Results on November 11, 2015
BELGRADE, Mont., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended September 30, 2015, at t
Read more →XTNTXtant Medical Holdings Begins Trading on NYSE MKT Under Symbol "XTNT"
Xtant Medical Holdings Begins Trading on NYSE MKT Under Symbol "XTNT" BELGRADE, Mont., Oct. 19, 2015 -- Xtant Medical Holdings, Inc. (XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its common stock will begin tra
Read more →XTNTXtant Medical Holdings Announces Uplisting to
Xtant Medical Holdings Announces Uplisting to Oct. 15, 2015 -- Xtant Medical Holdings, Inc. (BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its common stock has been approved for listing on the NYSE MKT. The compan
Read more →XTNTXtant Medical Holdings Announces Uplisting to NYSE MKT
BELGRADE, Mont., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its common stock has been approved for listing on the NYSE MKT. The company’s common sto
Read more →XTNTXtant Announces Preliminary Third Quarter 2015 Revenue
Third Quarter 2015 Pro Forma Combined Revenue in the range of $20.7 million to $20.9 million, an increase of 5.5 % to 6.5 % over the same period last year Excluding OEM Revenue, Third Quarter 2015 Pro Forma Combined Revenue expected to increase between 12.7% to 13.8% compared to
Read more →XTNTXtant TM Announces Preliminary Third Quarter 2015 Revenue Third Quarter 2015 Pro Forma Combined Revenue in the range of $20.7 million to $20.9 million, an increase of 5.5 % to 6.5 % over the same period last year Excludi
Announces Preliminary Third Quarter 2015 Revenue Xtant Medical Holdings, Inc. (OTCQX: BONE), a leader in the development of regenerative medicine products and medical devices, today announced preliminary unaudited revenue for the third quarter of 2015. The Company is expectin
Read more →XTNTXtant(TM) Medical Exhibits at North American Spine Society (NASS) Meeting
BELGRADE, Mont., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiaries, X-spine Systems Inc. and Bacterin International, In
Read more →XTNTXtant Medical Exhibits at North American Spine Society (NASS) Meeting Belgrade, Mont.
Xtant Medical Exhibits at North American Spine Society (NASS) Meeting October 12, 2015 - Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiaries, X-spine S
Read more →XTNTXtant Medical Awarded Grant from the Montana Board of Research And Commercialization Technology
Medical Awarded Grant from the Montana Board of Research And Commercialization Technology Mont., October 6, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced tha
Read more →XTNTXtant(TM) Medical Awarded Grant From the Montana Board of Research and Commercialization Technology
BELGRADE, Mont., Oct. 06, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, Bacterin International, Inc., has been awarded a gran
Read more →XTNTXtant(TM) Medical Exhibits at the Congress of Neurological Surgeons Annual Meeting
BELGRADE, Mont., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiaries, X-spine Systems and Bacterin International will be
Read more →XTNTXtant Medical Exhibits at the Congress of Neurological Surgeons Annual Meeting Belgrade, MT, USA- Xtant Medical Holdings, Inc. (OTCQX: BONE ), a leader in the development of regenerative medicine products and medical dev
Xtant Medical Exhibits at the Congress of Neurological Surgeons Annual Meeting Belgrade, MT, USA- Xtant Medical Holdings, Inc. (OTCQX: BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiaries,
Read more →XTNTXtant(R) Medical Announces Expanded Patent Coverage of Core Technologies
BELGRADE, Mont., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, Bacterin International, Inc., has received notificat
Read more →XTNTXtant TM Medical Announces Expanded Patent Coverage of Core Technologies
XtantTM Medical Announces Expanded Patent Coverage of Core Technologies Mont., September 22, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly o
Read more →XTNTXtant Medical Announces FDA Clearance of the Aranax Cervical Plate Belgrade, MT (Business Wire)
Medical Announces FDA Clearance of the Aranax Cervical Plate Belgrade, MT (Business Wire) September 9, 2015 - Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned sub
Read more →XTNTXtant Medical to Exhibit at EUROSPINE 2015 Belgrade, MT, USA- Xtant Medical Holdings, Inc. (OTCQX: BONE ), a leader in the development of regenerative medicine products and medical devices, today announced that its wholl
Xtant Medical to Exhibit at EUROSPINE 2015 Belgrade, MT, USA- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, Inc., will exhibit at
Read more →XTNTXtant Medical to Exhibit at EUROSPINE 2015
BELGRADE, Mont., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, Inc., will exhibit at EUROSPINE 2015
Read more →XTNTXtant Medical to Present at the Rodman Renshaw 17th Annual Global Investment Conference
Xtant Medical to Present at the Rodman Renshaw 17th Annual Global Investment Conference BELGRADE, Mont., August 27, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading
Read more →XTNTXtant Medical Announces FDA Approval of OsteoSelect
Medical Announces FDA Approval of OsteoSelect PLUS BELGRADE, Mont., Aug. 25, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary,
Read more →XTNTX-spine Systems, Inc. Consolidated Financial Report (Reviewed)
X-spine Systems, Inc. Consolidated Financial Report Financial Statements Consolidated Balance Sheets (Unaudited) 2-3 Consolidated Statements of Income (Unaudited) 4 Consolidated Statements of Retained Earnings (Unaudited) 5 Consolidated Statements of Cash Flows (Unaudited) 6 N
Read more →XTNTXtant Medical Reports First Half 2015 Financial Results
First Half Xtant(TM) Medical Pro Forma Combined 2015 Highlights: On July 31, 2015, the Company announced the close of its acquisition of X-spine Systems, Inc. Pro forma combined revenue increased 12.6% to $43.4 million from $38.5 million in the first half of 2014 Pro forma gro
Read more →XTNTXtant Medical Holdings, Inc. to Report Second Quarter 2015 Financial Results on
Xtant Medical Holdings, Inc. to Report Second Quarter 2015 Financial Results on August 12, 2015 BELGRADE, Mont., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary bone graft material, today announced that
Read more →XTNTXtant Medical Reports First Half 2015 Financial Results First Half Xtant (TM) Medical Pro Forma Combined 2015 Highlights: On
Reports First Half 2015 Financial Results First Half Xtant(TM) Medical Pro Forma Combined 2015 BELGRADE, Mont., Aug. 12, 2015 (GLOBE NEWSWIRE) - Xtant Medical Holdings, Inc. (OTCQX:BONE), formerly Bacterin International Holdings, Inc., a leader in the development of class-lead
Read more →XTNTBacterin CLOSES Purchase OF the Outstanding Common Stock of X-spine Systems, Inc. Combines Bacterin's strength in orthobiologics with X-spine's expertise in hardware offering complementary product lines focused on orthop
CLOSES Purchase OF the Outstanding Common Stock of X-spine Systems, Inc. Combines Bacterin's strength in orthobiologics with X-spine's expertise in hardware offering complementary product lines focused on orthopedic and spine surgical procedures. BELGRADE, Mont., July 31, 2015
Read more →XTNTBacterin to Purchase the Outstanding Common Stock of X-spine Systems, Inc., Creating Xtant Medical Combines Bacterin's strength in orthobiologics with X-spine's expertise in hardware offering comple
Bacterin to Purchase the Outstanding Common Stock of X-spine Systems, Inc., Creating Xtant Medical Combines Bacterin's strength in orthobiologics with X-spine's expertise in hardware offering complementary product lines focused on orthopedic and spine surgical procedures. Mon
Read more →XTNTBacterin Annouces Preliminary Second Quarter Revenue Second Quarter total revenue in the range of $10.0. million to $10.2 million, an increase of approximately 12-15% over the same period last year.
Bacterin Annouces Preliminary Second Second Quarter total revenue in the range of $10.0. million to $10.2 million, an increase of approximately 12-15% over the same period last year. Mont. - July 9, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (OTCQX:BONE),
Read more →XTNTBacterin International Holdings, Inc Awarded Agreement with Premier, Inc.
Bacterin International Holdings, Inc Awarded Agreement with Premier, Inc. 24, 2015 - Bacterin International Holdings, Inc. (OTCQX: BONE) has been awarded a new group purchasing agreement for the Bone Tissue Synthetic Implantable Products Category with Premier, Inc. Effective
Read more →XTNTBacterin International announces signing of agreement with Yankee Alliance
Bacterin International announces signing of agreement with Yankee Alliance BELGRADE, Mont., June 19, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (OTCQX: BONE), a leader in the development of revolutionary biomaterials, today announced the signing of an agre
Read more →XTNTBacterin Announces the Launch of ArthroFuse
Announces the Launch of ArthroFuse Mont., June 3, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (OTCQX: BONE), a leader in the development of revolutionary biomaterials, today announced the release of ArthroFuse, a patent pending allograft specifically designed
Read more →XTNTCORRECTING AND REPLACING Bacterin Sets Annual Meeting and Record Dates BELGRADE, Mont. - (BUSINESS WIRE)
CORRECTING AND REPLACING Bacterin Sets Annual Meeting Mont.-(BUSINESS WIRE) - May 15, 2015 - Bacterin International Holdings, Inc. (OTCQX: BONE), a leader in the development of revolutionary bone graft material, has established a record date for its 2015 annual meeting Bacte
Read more →XTNTBacterin Record Announces First Quarter 2015 Results Company Continues to See Record Revenue Growth, Gross Profit Increases and Improved Gross Margins First Quarter Highlights: Total revenue increased 6.6% to $9.5 millio
Bacterin Record Announces First Quarter Company Continues to See Record Revenue Growth, Gross Profit Increases and Improved Gross Margins First Quarter Highlights: BELGRADE, Mont., May 5, 2015 (GLOBE NEWSWIRE) - Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in
Read more →XTNTWIRE) - May 4, 2015 - Bacterin International Holdings, Inc.
BELGRADE, Mont.-(BUSINESS WIRE) - May 4, 2015 - Bacterin International Holdings, Inc. (OTCQX: BONE), a leader in the development of revolutionary bone graft material, has established a record date for its 2015 annual meeting of stockholders. Bacterin stockholders of record at
Read more →XTNTBacterin International Receives Coverage From Medicare Administrative Contractor (MAC) for hMatrix
Bacterin International Receives Coverage From Medicare Administrative Contractor (MAC) for hMatrix BELGRADE, Mont., April 28, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary allograft, today announced t
Read more →XTNTBacterin to Report First Quarter 2015 Financial Results on
Bacterin to Report First Quarter 2015 Financial Results on May 5, 2015 BELGRADE, MT, April 23, 2015 -- Bacterin International Holdings, Inc. (OTCQX: BONE), a leader in the development of revolutionary bone graft material, today announced that it will release its financial res
Read more →XTNTBacterin Announces Preliminary First Quarter 2015 Results First Quarter total revenue expected to be in the range of $9.4 million to $9.5 million, an increase of approximately 5-7% over the same period last year. BELGRAD
Bacterin Announces Preliminary First Quarter 2015 Results First Quarter total revenue expected to be in the range of $9.4 million to $9.5 million, an increase of approximately 5-7% over the same period last year. Mont. - APRIL 9, 2015, - Bacterin International Holdings, Inc.
Read more →XTNTBacterin International to Begin Trading on OTCQX Marketplace BELGRADE, Mont .
Bacterin International to Begin Trading on OTCQX Marketplace Mont. - April 8, 2015, - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material, today announced that it received written notice from the staff at NYS
Read more →XTNTBacterin Announces OsteoSponge Patent BELGRADE, MT
Announces OsteoSponge Patent MT, April 6, 2015 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts, is pleased to announce that the United States Patent and Trademark Office has issued US Patent No. 8,992,964 entitl
Read more →XTNTBacterin Announces Fourth Quarter and Year-End 2014 Results Fourth Quarter Highlights: Total revenue increased to $9.1 million from $8.3 million in Q4 2013, an increase of 10.0% over the prior year Gross profit increased
Bacterin Announces Fourth Quarter and Year-End 2014 Results Fourth Quarter Highlights: BELGRADE, Mont., March 17, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of bone graft material, today reported financial resul
Read more →XTNTBacterin Announces Contract Extension With Novation
Contract Extension With Novation BELGRADE, Mont., March 16, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of bone graft material, today announced that it has extended its contract with Novation for an additional yea
Read more →XTNTBacterin to Present at the Canaccord Genuity Musculoskeletal Conference
Bacterin to Present at the Canaccord Genuity Musculoskeletal Conference BELGRADE, Mont., March 11, 2015 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone grafts, today announced that its CEO, Dan Goldb
Read more →XTNTBacterin Announces Distribution Agreement with Spartan Medical for DOD and VA Medical Centers BELGRADE, MT--(BUSINESS WIRE)
Bacterin Announces Distribution Agreement with Spartan Medical for DOD and VA Medical Centers BELGRADE, MT--(BUSINESS WIRE) March 10, 2015 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material, today announced it has sig
Read more →XTNTBacterin to Report Fourth Quarter 2014 Financial Results on
BELGRADE, MT, March 2, 2015 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material, today announced that it will release its financial results for the period and full year ended December 31, 2014, on March 17,
Read more →XTNTBacterin To Present at the 27th Annual Roth Conference BELGRADE, MT
Bacterin To Present at the 27th Annual Roth BELGRADE, MT, February 24, 2015 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts, today announced that its CEO, Dan Goldberger, will present at the 2015 27th Annual
Read more →XTNTBacterin Announces 1000 th Lot of OsteoSelect DBM Putty BELGRADE, MT--(BUSINESS WIRE)
Bacterin Announces 1000th Lot of OsteoSelect DBM Putty BELGRADE, MT--(BUSINESS WIRE)- February 17, 2015 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medical applications, today announced that it
Read more →XTNTBacterin Announces Preliminary Fourth Quarter 2014 Revenue Fourth Quarter total revenue in the range of $8.9 million to $9.1 million, an increase of approximately 8-10% over the same period last year. BELGRADE, Mont .
Bacterin Announces Preliminary Fourth Quarter 2014 Revenue Mont. - January 12, 2015, - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced preliminary u
Read more →XTNTBacterin To Present at the 7 th Annual LD Micro Conference BELGRADE, MT
at the 7th Annual LD Micro BELGRADE, MT, November 26, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CFO, John Gandolfo, will present at th
Read more →XTNTBacterin To Present at the Singular Research 9th Annual Best of the Uncovereds Conference BELGRADE, MT
Bacterin To Present at the Singular Research 9th Annual Best of the Uncovereds Conference BELGRADE, MT, November 17, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications,
Read more →XTNTBacterin Receives Delisting Notice from
Bacterin Receives Delisting Notice from BELGRADE, Mont., November 14, 2014 (GLOBE NEWSWIRE) - Bacterin International Holdings, Inc. (NYSE: BONE) today announced that the Company received notice that the staff of NYSE Regulation, Inc. has determined to commence proceedings to d
Read more →XTNTBacterin CEO Dan Goldberger to be Guest on Fox Business Network's After the Bell with Liz Claman
Bacterin CEO Dan Goldberger to be Guest on Fox Business Network's After the Bell with Liz Claman BELGRADE, Mont., November 11, 2014 (GLOBE NEWSWIRE) -- Bacterin International Holdings, Inc. (NYSE:BONE) today announced its CEO Dan Goldberger will be a guest on FOX Business Netw
Read more →XTNTBacterin Announces Third Quarter 2014 Results Company increases year-over-year sales, improves margins and reduces loss from operations Third Quarter Highlights: Third Quarter 2014 total revenue increased approximately 6
Bacterin Announces Third Quarter 2014 Company increases year-over-year sales, improves margins and reduces loss from operations Third Quarter Highlights: BELGRADE, MT--(BUSINESS WIRE) November 5, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the
Read more →XTNTBacterin Announces Further Expansion of its Sales Force BELGRADE, MT- (GLOBE NEW SWIRE)
Bacterin Announces Further Expansion BELGRADE, MT- (GLOBE NEW SWIRE) - November 5, 2014 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and bioactive coatings for medical applications, today announced three senior ad
Read more →XTNTBacterin to Showcase New Product Line at the North American Spine Society Annual Meeting BELGRADE, MT--(BUSINESS WIRE)
Bacterin to Showcase New Product Line at the North American Spine Society Annual Meeting BELGRADE, MT--(BUSINESS WIRE) - November 4, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and bioactive coatings for me
Read more →XTNTBacterin Awarded Grant from the Montana Board of Research and Commercialization Technology BELGRADE, MT--(BUSINESS WIRE)
Bacterin Awarded Grant from the Montana Board of Research and Commercialization Technology BELGRADE, MT--(BUSINESS WIRE)- October 27, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medical app
Read more →XTNTBacterin to Report Third Quarter 2014 Financial Results on
Bacterin to Report Third Quarter 2014 Financial Results on November 5, 2014 BELGRADE, MT, October 23, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today
Read more →XTNTBacterin Presents Preclinical Results of an Efficacious Antimicrobial Orthopedic Device Coating BELGRADE, MT--(BUSINESS WIRE)
Bacterin Presents Preclinical Results of an Efficacious Antimicrobial Orthopedic Device Coating BELGRADE, MT--(BUSINESS WIRE)- October 22, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medica
Read more →XTNTBacterin Announces 3Demin Cortical Fibers BELGRADE, MT--(BUSINESS WIRE)
Bacterin Announces 3Demin Cortical BELGRADE, MT--(BUSINESS WIRE) - October 20, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medical applications, today announced the launch of a demineralize
Read more →XTNTCORRECTING AND REPLACING Bacterin Announces Preliminary Third Quarter 2014 Revenue Third Quarter total revenue in the range of $8.3 million to $8.5 million, an increase of approximately 4-7% over the same period last yea
CORRECTING AND REPLACING Bacterin Announces Preliminary Third Quarter 2014 Revenue Mont. - Oct. 16, 2014 (GLOBE NEWSWIRE) -- In a release issued on Tuesday, October 14th 2014 by Bacterin International Holdings, Inc. (NYSE MKT: BONE), there was an error in the third paragraph
Read more →XTNTBacterin International Announces Sales Team Expansion Bacterin attracts industry top sales management talent Belgrade, MT
Bacterin International Announces Sales Team Expansion industry top sales management talent Belgrade, MT- October 16, 2014 - Bacterin announced today three senior executive additions to its hybrid sales channel. Jeff Whitaker has joined us as Regional Vice President in the S
Read more →XTNTBacterin Announces Preliminary Third Quarter 2014 Revenue Third Quarter total revenue expected to be in the range of $8.4 million to $8.5 million, an increase of approximately 6 - 7% over the same period last year.
Third Quarter total revenue expected to be in the range of $8.4 million to $8.5 million, an increase of approximately 6 - 7% over the same period last year. Mont. - October 14, 2014, - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revol
Read more →XTNTBacterin CEO Dan Goldberger to be Guest on Fox Business Network's Opening Bell with Maria Bartiromo Belgrade, Mont.
Bacterin CEO Dan Goldberger Business Network's Opening Bell with Maria Bartiromo Belgrade, Mont., October 2, 2014 - Bacterin International Holdings, Inc. (NYSE MKT: BONE) today announced its CEO Dan Goldberger will be a guest on FOX Business Network's Opening Bell with Maria
Read more →XTNTBacterin Announces the Appointment of New Board Member BELGRADE, Mont.--(BUSINESS WIRE)
Bacterin Announces the Appointment of New BELGRADE, Mont.--(BUSINESS WIRE) - August 13, 2014 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce
Read more →XTNTBacterin Announces Second Quarter 2014 Results Second Quarter 2014 Revenues Increase Approximately 7.5% Over Second Quarter 2013 BELGRADE, MT -(BUSINESS WIRE)
Second Quarter 2014 Results Second Quarter 2014 Revenues Increase Approximately 7.5% Over Second Quarter 2013 MT-(BUSINESS WIRE)- August 12, 2014 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medi
Read more →XTNTBacterin Announces Publication in The Spine Journal Featuring OsteoSelect DBM Putty
Announces Publication in The Spine Journal Featuring OsteoSelect DBM Putty BELGRADE, Mont., August 12, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft materials and bioactive coatings for medical applications, announced
Read more →XTNTBacterin Announces Closing of Public Offering of Common Stock BELGRADE, MT
Announces Closing of Public Offering of Common Stock BELGRADE, MT, August 6, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medical applications, today announced the completion of its previous
Read more →XTNTBacterin Announces Clinical Results on the use of OsteoSponge SC Allograft Published in The Journal of Foot & Ankle Surgery
Announces Clinical Results on the use of OsteoSponge Allograft Published in The Journal of Foot & Ankle Surgery BELGRADE, Mont., August 5, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft materials and bioactive coatings
Read more →XTNTBacterin Announces Pricing of Public Offering of Common Stock BELGRADE, MT
Announces Pricing of Public Offering of BELGRADE, MT, August 1, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medical applications, today announced the pricing of its previously announced und
Read more →XTNTBacterin Announces Public Offering of Common Stock BELGRADE, MT
Bacterin Announces Public Offering of Common Stock BELGRADE, MT, July 31, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of bone graft material and coatings for medical applications, today announced that it intends to offer shares
Read more →XTNTBacterin to Report Second Quarter 2014 Financial Results on
Bacterin to Report Second Quarter 2014 Financial Results on August 12, 2014 BELGRADE, MT, July 29, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today ann
Read more →XTNTBacterin Announces Reverse Split of Common Stock
Announces Reverse Split of Common Stock Mont. - July 23, 2014, - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that a 1:10 reverse split of its co
Read more →XTNTBacterin Announces Preliminary Second Quarter 2014 Results Second Quarter total revenue expected to be in the range of $8.75 million to $8.85 million, an increase of approximately 6-7% over the same period last year.
Bacterin Announces Preliminary Second Quarter Mont. - July 21, 2014, - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced preliminary unaudited results
Read more →XTNTBacterin Announces the Appointment of Robert Di Silvio as President BELGRADE, Mont.--(BUSINESS WIRE)
the Appointment of Robert Di Silvio as President BELGRADE, Mont.--(BUSINESS WIRE) - July 1, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to ann
Read more →XTNTBacterin To Present at the 2014 Newport Coast Securities, Inc. Annual Equity & National Sales Conference BELGRADE, MT
at the 2014 Newport Coast Securities, Inc. Annual Equity & National Sales Conference 10, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CFO,
Read more →XTNTBacterin Announces First Quarter 2014 Results Company reports record core recurring biologics revenues of $8.7 million BELGRADE, Mont .--(BUSINESS WIRE)
First Quarter 2014 Results Company reports record core recurring biologics revenues of $8.7 million BELGRADE, Mont.--(BUSINESS WIRE)- May 06, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and
Read more →XTNTthe Appointment of a Vice President of Sales
the Appointment of a Vice President of Sales Mont.-(BUSINESS WIRE) - May International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Melanie Head a
Read more →XTNTBacterin to Report First Quarter 2014 Financial Results on
Bacterin to Report First Quarter 2014 Financial Results on May 7, 2014 28, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it will relea
Read more →XTNTBacterin Announces Preclinical Results on the use of OsteoSelect DBM Putty Published in The Journal of Craniofacial Surgery
Announces Preclinical Results on the use of OsteoSelect DBM Putty Published in The Journal of Craniofacial Surgery BELGRADE, Mont., April 23, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and b
Read more →XTNTBacterin Announces Preliminary First Quarter 2014 Revenue Core recurring Biologics revenues up 20% from prior year First Quarter total revenue in the range of $8.7 million to $8.9 million, an increase of approximately 7%
Bacterin Announces Preliminary First Quarter Core recurring Biologics revenues up 20% Mont. - April 21, 2014, - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, anno
Read more →XTNTBacterin Announces the Addition of Two Vice Presidents BELGRADE, Mont.--(BUSINESS WIRE)
Announces the Addition of Two Vice Presidents Mont.--(BUSINESS WIRE)- April 8, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addit
Read more →XTNTClinical Results on the use of Bacterin's OsteoSponge for Foot and Ankle Arthrodeses Procedures Published in Orthopedics Today
Clinical Results on the use of Bacterin's OsteoSponge for Foot and Ankle Arthrodeses Procedures Published in Orthopedics Today BELGRADE, Mont., March 20, 2014 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary b
Read more →XTNTBacterin Announces Full Year 2013 Results BELGRADE, Mont .--(BUSINESS WIRE)
Full Year 2013 Results BELGRADE, Mont.--(BUSINESS WIRE)- March 19, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported financial results for the f
Read more →XTNTBacterin Announces the Launch of OsteoSTX, a Novel Biologic Product BELGRADE, MT
Bacterin Announces the Launch of OsteoSTX, a Novel Biologic Product BELGRADE, MT, March 13, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin's prop
Read more →XTNTBacterin Secures Additional OrbiMed Financing BELGRADE, MT
Secures Additional OrbiMed Financing March 10, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, announced the closing of an additional $4 million financing fro
Read more →XTNTBacterin Announces Earnings Release and Conference Call Date for 2013 Fourth Quarter and Full Year Results BELGRADE, MT
Bacterin Announces Earnings Conference Call Date for 2013 Fourth Quarter and Full BELGRADE, MT, February 25, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications,
Read more →XTNTBacterin to Present at the Canaccord Genuity Musculoskeletal Conference BELGRADE, MT
at the Canaccord Genuity Musculoskeletal Conference BELGRADE, MT, February 19, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CEO, Dan Gold
Read more →XTNTBacterin to Present at the Leerink Global Healthcare Conference BELGRADE, MT
Bacterin to Present at the Leerink Global Healthcare Conference BELGRADE, MT, February 4, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its C
Read more →XTNTBacterin Announces Preliminary Fourth Quarter 2013 Revenue Fourth Quarter Revenue in the range of $8.15 million to $8.28 million, an increase of 4% sequentially, and 1.5% over the same period last year. Fourth Quarter Bi
Bacterin Announces Preliminary Fourth Quarter 2013 Revenue BELGRADE, Mont. January 23, 2014, Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, announced today prelimi
Read more →XTNTBacterin to Present at the Noble Financial Tenth Annual Equity Conference BELGRADE, MT
Bacterin to Present at the Noble Financial Tenth Annual Equity Conference BELGRADE, MT, January 15, 2014 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced
Read more →XTNTBacterin Announces 2014 Donate Life Rose Parade Float Living Donor Honoree BELGRADE, Mont.--(BUSINESS WIRE)--Dec.31, 2013-- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce Kevin Noyes as its
Bacterin Announces 2014 Donate Life Rose Parade Float Living Donor Honoree BELGRADE, Mont.--(BUSINESS WIRE)--Dec.31, 2013-- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce Kevin Noyes as its 2014 Donate Life Rose Parade Float Living Donor Honoree
Read more →XTNTBacterin International Holdings, Inc. CEO Dan Goldberger to Be Interviewed on Clear Channel DFW 1109AM Dan Goldberger to Be Interviewed Live Dec 20th on Traders Financial Network Radio Show by Host Michael Yorba BELGRADE
Bacterin International Holdings, Inc. CEO Dan Goldberger to Be Interviewed on Clear Channel DFW 1109AM Dan Goldberger to Be Interviewed Live Dec 20th on Traders Financial Network Radio Show by Host Michael Yorba BELGRADE, Mont.--(Dec 20th 2013)- Bacterin International Holdin
Read more →XTNTBACTERIN
BACTERIN ANNOUNCES APPOINTMENT OF CANADIAN DISTRIBUTOR MT, December 18, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and coatings for medical applications, today announced the appointment of O
Read more →XTNTBACTERIN ANNOUNCES 2014
BACTERIN ANNOUNCES 2014 DONATE LIFE ROSE PARADE FLOAT FLORAGRAPH HONOREE BELGRADE, Mont., December 5, 2013 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce Rita Cihak as its' 2014 Donate Life Rose Parade Float Floragraph Honoree. R
Read more →XTNTBacterin to Present at the LD Micro Conference BELGRADE, MT
at the LD Micro Conference BELGRADE, MT, November 26, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CEO, Dan Goldberger, and CFO, John Gan
Read more →XTNTBacterin Receives Deficiency Notice from
Bacterin Receives Deficiency Notice from MT, November 22, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that that the NYSE MKT LLC (the "Exchange")
Read more →XTNTPositive Clinical Results on the use of Bacterin's OsteoSponge for Transforaminal Lumbar Interbody Fusion (TLIF) Published in International Journal of Spine Surgery
Positive Clinical Results on the use of Bacterin's OsteoSponge for Transforaminal Lumbar Interbody Fusion (TLIF) Published in International Journal of Spine Surgery BELGRADE, Mont., November 21, 2013 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a lea
Read more →XTNTBacterin Ranked in Deloitte ' s Technology Fast 500 BELGRADE, MT
Ranked in Deloitte's Technology Fast 500 MT, November 19, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced it ranked on Deloitte's Technology
Read more →XTNTThird Quarter 2013 Results
Third Quarter 2013 Results Total revenue, excluding stocking orders, increased 12.9% over the prior year period BELGRADE, Mont.-(BUSINESS WIRE)- NOVEMBER 7, 2013, 2013- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone
Read more →XTNTBacterin Announces Strategic Alliance to Distribute Products into European Markets BELGRADE, MT
Bacterin Announces Strategic Alliance to Distribute Products into European Markets MT, November 7, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and coatings for medical applications, today ann
Read more →XTNTBacterin Awarded Patent for Method to Produce Demineralized Bone Matrix BELGRADE, MT
Bacterin Awarded Patent for Method to Produce Demineralized Bone MT, November 6, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and coatings for medical applications, today announced that the U
Read more →XTNTBacterin Announces Earnings Release and Conference Call Date for 2013 Third Quarter Results BELGRADE, MT
Bacterin Announces Earnings Conference Call Date for 2013 Third Quarter Results BELGRADE, MT, October 22, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, to
Read more →XTNTBacterin to Host Initial Investor Call with CEO Dan Goldberger BELGRADE, MT
Bacterin to Host Initial Investor Call with CEO Dan Goldberger BELGRADE, MT, September 4, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced th
Read more →XTNTBacterin to Present at The Rodman & Renshaw Annual Global Investment Conference BELGRADE, MT
Bacterin to Present at The Rodman & Renshaw Annual Global Investment Conference BELGRADE, MT, August 27, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, tod
Read more →XTNTBacterin Reports Inducement Grant in accordance with Section 711(a) of the NYSE MKT Company Guide BELGRADE, MT
Bacterin Reports Inducement with Section 711(a) of the NYSE MKT Company Guide MT, August 21, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced
Read more →XTNTBacterin Announces New
Bacterin Announces New CEO BELGRADE, Montana , August 7, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that Daniel "Dan" Goldberger has agr
Read more →XTNTBacterin Announces Second Quarter 2013 Results Highlights: Revenue increased to $8.3 million from $8.2 million reported during the second quarter of 2012 Revenues for the period, excluding distributor stocking orders, in
Second Quarter 2013 Results BELGRADE, Montana , August 6, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported its financial results for the second
Read more →XTNTBacterin Announces Earnings Release and Conference Call Date for 2013 Second Quarter Results BELGRADE, MT
Bacterin Announces Earnings Release and Conference Call Date for 2013 Second Quarter Results 24, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announ
Read more →XTNTBacterin's OsteoSelect DBM Putty Approved for Spinal Fusion Applications
Bacterin's OsteoSelect DBM Putty Approved for Spinal Fusion Applications BELGRADE, Mont., July 16, 2013 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical application
Read more →XTNTBacterin Receives Acceptance of Plan to Regain Compliance from
Bacterin Receives Acceptance of Plan to Regain Compliance from NYSE MKT BELGRADE, MT, June 25, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announc
Read more →XTNTBacterin International Announces Financing BELGRADE, MT
Bacterin International Announces Financing BELGRADE, MT, June 5, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it has entered into a d
Read more →XTNTBacterin Receives Compliance Notice from
Bacterin Receives Compliance Notice from BELGRADE, MT, May 16, 2013 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it has received a complian
Read more →XTNTBacterin Announces First Quarter 2013 Revenue of $8.6 Million First Quarter 2013 Highlights: Revenue increased 11% year over year, to approximately $8.6 million, and increased 6% over reported revenues for the fourth qua
Bacterin Announces First Quarter 2013 Revenue of $8.6 Million BELGRADE, MT, May 9, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported its financ
Read more →XTNTBacterin Announces Earnings Release and Conference Call Date for 2013 First Quarter Results BELGRADE, MT
Bacterin Announces Earnings Release and Conference Call Date for 2013 First Quarter Results 30, 2013 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announce
Read more →XTNTBacterin Announces Selection of Executive Search Firm BELGRADE, MT
Bacterin Announces Selection Executive Search Firm 26, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced the selection of O'Hara Associates, In
Read more →XTNTBacterin Provides Update on Executive Leadership Transition Plans Company in final stages of identifying search firm; several candidates express interest BELGRADE, MT
Bacterin Provides Update on Executive Leadership Transition Plans Company in final stages of identifying search firm; several candidates express interest 17, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graf
Read more →XTNTBacterin Announces Transition of Executive Leadership Company has begun process to identify candidates for Chief Executive Officer BELGRADE, MT
Bacterin Announces Transition of Executive Leadership Company has begun process to identify candidates for Chief Executive Officer 1, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings
Read more →XTNTBacterin Announces Record 2012 Revenue of $33 Million Full Year 2012 Highlights: Revenue increased 9% to approximately $33.0 million in 2012, compared to approximately $30.1 million for fiscal year 2011 Loss from operati
Bacterin Announces Record 2012 Revenue of $33 Million Full Year 2012 Highlights: Fourth Quarter 2012 Highlights: BELGRADE, MT, March 26, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coati
Read more →XTNTBacterin Announces Earnings Release And Conference Call Date For 2012 Fourth Quarter & Year End Results BELGRADE, MT
Bacterin Announces Earnings Release And Conference Call Date For 2012 Fourth Quarter & Year End Results BELGRADE, MT - March 13, 2013 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for m
Read more →XTNTBacterin International Holdings, Inc. Announces ISO Certification BELGRADE, MT
Bacterin International Holdings, Inc. Announces BELGRADE, MT - February 26, 2013 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it has achiev
Read more →XTNTBacterin International Holdings, Inc. Announces Fourth Quarter Revenues BELGRADE, MT
Bacterin International Holdings, Inc. Fourth Quarter Revenues BELGRADE, MT - February 20, 2013 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, today
Read more →XTNTBacterin's OsteoSponge Product Generates Positive Clinical Results Clinical Results for Foot and Ankle Fusion Published in "The Journal of Foot & Ankle Surgery." BELGRADE, MT
Bacterin's OsteoSponge Generates Positive Clinical Results Clinical Results for Foot and Ankle Fusion Published in "The Journal of Foot & Ankle Surgery." BELGRADE, MT - January 22, 2013 - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of
Read more →XTNTBacterin Reports Third Quarter 2012 Financial Results Revenue Increases 18%; Company Reports 71% Gross Margins and Attains Operational Profitability Conference Call at 4:30pm ET to Discuss Third Quarter 2012 Results
Bacterin Reports Third Quarter 2012 Financial Results Revenue Increases 18%; Company Reports 71% Gross Margins and Attains Operational Profitability Conference Call at 4:30pm ET to Discuss Third Quarter BELGRADE, Mont. November 07, 2012 - Bacterin International Holdings, In
Read more →XTNTBacterin International Holdings, Inc. Schedules Third Quarter 2012 Financial Earnings Conference Call
Bacterin International Holdings, Inc. Schedules Third Quarter 2012 Financial Earnings Conference Call BELGRADE, Mont. Oct. 23, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial co
Read more →XTNTBacterin to Present at 7th Annual Singular Research Conference
Bacterin to Present at 7th Annual Singular Research Conference BELGRADE, Mont., October 23, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical appl
Read more →XTNTJohn Deedrick Joins Bacterin Board of Directors
John Deedrick Joins Bacterin Board of Directors BELGRADE, Mont., September 12, 2012 /PRNewswire/ - Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, anno
Read more →XTNTPositive Clinical Results on the use of Bacterin's OsteoSponge SC Product for Regeneration of Subchondral Bone Published in Foot & Ankle Specialist All patients reported a clinically significant reduction in pain and imp
Positive Clinical Results on the use of Bacterin's OsteoSponge SC Product for Regeneration of Subchondral Bone Published in Foot & Ankle Specialist All patients reported a clinically significant reduction in pain and improvement in activity at six months post-operation relativ
Read more →XTNTBacterin International to Present at Stifel Nicolaus 2012 Healthcare Conference on
International to Present at Stifel Nicolaus 2012 Healthcare Conference Mont. August 31, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will pre
Read more →XTNTBacterin Secures $25 Million Financing with OrbiMed Funding provides significant flexibility to execute growth strategy
Bacterin Secures $25 Million Financing Funding provides significant flexibility to execute growth strategy BELGRADE, Mont. Aug. 28, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of unique bone graft material and antimicrobial coat
Read more →XTNTBacterin International Announces Second Quarter and Six Months 2012 Financial Results -Second Quarter Revenue Increases 9% to $8.2 Million Year over Year -Six Month Revenue Increases 18% to $16.0 Million Year over Year -
Bacterin International Announces Second Quarter and Six Months 2012 Financial Results -Second Quarter Revenue Increases 9% to $8.2 Million Year over Year -Six Month Revenue Increases 18% to $16.0 Million Year over Year - Company Exits a Backorder Status on a Large Producti
Read more →XTNTBacterin International Holdings, Inc. Schedules Second Quarter 2012 Financial Earnings Conference Call
Bacterin International Holdings, Inc. Schedules Second Quarter 2012 Financial Earnings Conference Call BELGRADE, Mont. July. 27, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial
Read more →XTNTBacterin International Signs Its Fourth National GPO Contract with the Premier healthcare alliance
Bacterin International Signs Its Fourth National GPO Contract with the Premier healthcare alliance BELGRADE, Mont., July 10, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and anti
Read more →XTNTBacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders BELGRADE, Mont. J ULY 3, 2012 /PRNewswire/ - Bacterin International Holdings, Inc. (NYSE MKT LLC:
Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders BELGRADE, Mont. JULY 3, 2012 /PRNewswire/ - Bacterin International Holdings, Inc. (NYSE MKT LLC: BONE), a leader in the development of revolutionary bone
Read more →XTNTBacterin to Present at the Jefferies 2012 Global Healthcare Conference
Bacterin to Present at the Jefferies 2012 Global Healthcare BELGRADE, Mont. May. 30, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will prese
Read more →XTNTBacterin International Signs Its Third National GPO Contract with Novation
Bacterin International Signs Its Third National GPO Contract BELGRADE, Mont. May 8, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, announces i
Read more →XTNTBacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss Conference Call at 4:30pm ET to Discuss First Quarter 2012 Results
Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss Conference Call at 4:30pm ET to Discuss First Quarter 3, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader
Read more →XTNTBacterin International Holdings, Inc. Schedules First Quarter 2012 Financial Earnings Conference Call
Bacterin International Holdings, Inc. Schedules First Quarter 2012 Financial Earnings Conference Call BELGRADE, Mont. Apr. 24, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial co
Read more →XTNTBacterin Secures Accounts Receivable Credit Facility
Secures Accounts Receivable Credit Facility BELGRADE, Mont. Apr. 24, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has secured an accounts re
Read more →XTNTPeer Review Determines Bacterin's OsteoSponge Superior to Autograft and Ideal for Bone Regeneration in Dove Press Journal
Peer Review Determines Bacterin's OsteoSponge Superior to Autograft and Ideal for Bone Regeneration in Dove Press Journal BELGRADE, Mont. Apr. 4, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material an
Read more →XTNTBacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year Conference Call at 4:30pm ET to Discuss Full Year and Fourth Quarter 2011 Results
Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year Conference Call at 4:30pm ET to Discuss Full Year and Fourth Quarter 2011 Results BELGRADE, Mont. March 22, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the developm
Read more →XTNTBacterin To Present at the 5th Annual Maxim Group Growth Conference on
Bacterin To Present at the 5th Annual Maxim Group Growth Conference BELGRADE, Mont. Mar. 12, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, wi
Read more →XTNTBacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call BELGRADE, Mont. Feb. 24, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial co
Read more →XTNTBacterin Study at AAOS 2012 Annual Meeting Shows OsteoSponge Equivalence to rhBMP-2 in Spinal Fusion; Presented Specifically to Orthopaedic Surgeons
at AAOS 2012 Annual Meeting Shows Equivalence to rhBMP-2 in Spinal Fusion; Specifically to Orthopaedic Surgeons BELGRADE, Mont. Feb. 10, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antim
Read more →XTNTBacterin Promotes Seasoned Healthcare Sales Professional To National Sales Manager
Seasoned Healthcare Sales Professional BELGRADE, Mont. Feb. 7, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has promoted Nick Navarro, a sea
Read more →XTNTBacterin Retains Hayden IR to Develop Strategic Investor Relations Program Seeks to Expand Investor Awareness and Develop World-Class Communications Infrastructure as Company Executes Aggressive Growth Strategy BELGRADE,
to Develop Strategic Investor Relations Program Investor Awareness and Develop World-Class Communications Infrastructure as Company Executes Aggressive Growth Strategy BELGRADE, Mont. Feb. XX, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the dev
Read more →XTNTUnassociated Document Bacterin to Present at the Noble 8th Annual Equity Conference on
Bacterin to Present at the Noble 8th Annual Equity Conference on January 17, 2012 BELGRADE, MT, - January 11, 2012 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical a
Read more →XTNTUnassociated Document Bacterin Signs Distribution Agreement with Jeil for LeF rte Craniomaxillofacial System' Company Complements Core Technology with Craniomaxillofacial Trauma Set; Bacterin Appoints Nick Navarro as Exe
Bacterin Signs Distribution Agreement with Jeil for LeF rte Craniomaxillofacial System' Company Complements Core Technology with Craniomaxillofacial Trauma Set; Bacterin Appoints Nick Navarro as Executive Vice President of Medical Devices BELGRADE, MT, - November 28, 2011 - Ba
Read more →XTNTUnassociated Document Bacterin to Present at 4th Annual LD MICRO Conference on
Bacterin to Present at 4th Annual LD MICRO Conference on December 8, 2011 BELGRADE, MT, - November 22, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applicat
Read more →XTNTUnassociated Document Bacterin Reports Third Quarter 2011 Results Record Revenues of $7.5 Million, up 80% over Prior Year BELGRADE, MT
Bacterin Reports Third Quarter 2011 Results Record Revenues of $7.5 Million, up 80% over Prior Year BELGRADE, MT, - November 10, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial co
Read more →XTNTUnassociated Document Bacterin Becomes Premier Founding Sponsor of RMEC's New Osteobiologics Registry BELGRADE, MT
Bacterin Becomes Premier Founding Sponsor of RMEC's New Osteobiologics Registry BELGRADE, MT, - November 3, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical app
Read more →XTNTBacterin to Present at Lazard Capital Markets 8th Annual Healthcare Conference on
Bacterin to Present at Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011 BELGRADE, MT, - October 31, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coa
Read more →XTNTUnassociated Document Bacterin Sponsors the 2012 Donate Life Rose Parade Float in Recognition of Donor Families BOZEMAN & BELGRADE, MT
Bacterin Sponsors the 2012 Donate Life Rose Parade Float in Recognition of Donor Families BOZEMAN & BELGRADE, MT, - October 28, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coat
Read more →XTNTUnassociated Document Bacterin Study Shows OsteoSponge Equivalence to rhBMP-2 in Spinal Fusion BELGRADE, MT
Bacterin Study Shows OsteoSponge Equivalence to rhBMP-2 in Spinal Fusion BELGRADE, MT, - October 25, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applicatio
Read more →XTNTBacterinAwarded Approved Vendor Status for American Medical Concepts' Network of Hospitals in the Northwest U.S. BELGRADE, MT, - October24, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the
BacterinAwarded Approved Vendor Status for American Medical Concepts' Network of Hospitals in the Northwest U.S. BELGRADE, MT, - October24, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimi
Read more →XTNTBacterin International Sets Third Quarter 2011 Conference Call for Thursday
BELGRADE, MT, - October 17, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will hold a conference call on Thursday, November 10, 2011 at 4:30 p.m
Read more →XTNTBacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on
Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011 BELGRADE, MT, - August 24, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coa
Read more →XTNTUnassociated Document Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on
Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on September 12, 2011 BELGRADE, MT, - August 23, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimic
Read more →XTNTUnassociated Document Bacterin Second Quarter 2011 Revenues up 135% over Prior Year, Driving First Positive EBITDA Quarter BELGRADE, MT
Bacterin Second Quarter 2011 Revenues up 135% over Prior Year, Driving First Positive EBITDA Quarter BELGRADE, MT, - August 11, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coat
Read more →XTNTUnassociated Document Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July BELGRADE, MT
Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July BELGRADE, MT, - August 5, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and anti-infective co
Read more →XTNTBacterin Secures $15 Million Credit Facility with MidCap Financial and Silicon Valley Bank Proceeds to Retire Existing Debt Obligations, Provide Working Capital and Fund M&A Activity BELGRADE, MT
Bacterin Secures $15 Million Credit Facility with MidCap Financial and Proceeds to Retire Existing Debt Obligations, Provide Working Capital and Fund M&A BELGRADE, MT, - August 1, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of rev
Read more →XTNTUnassociated Document Bacterin Sets Second Quarter 2011 Conference Call for Thursday
Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET BELGRADE, MT, - July 26, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and anti-infective coatings
Read more →XTNTBacterin Acquires Assets of Robinson MedSurg
Bacterin Acquires Assets of Robinson MedSurg Company Prepares to Introduce Anti-Microbial Coated Orthopedic Implants BELGRADE, MT, - July 18, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and ant
Read more →XTNTBacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes BELGRADE, MT
Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes BELGRADE, MT, - June 27, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and anti-infective coatings for medical applicatio
Read more →XTNTBacterin Engages Liolios Group to Lead Investor Relations Program BELGRADE, MT
Bacterin Engages Liolios Group to Lead Investor Relations Program BELGRADE, MT, - June 21, 2011 - Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and anti-infective coatings for medical applications, has e
Read more →XTNTBacterin International Signs Its Second National GPO Contract for
Bacterin International Signs Its Second National GPO Contract for Bacterin Biologics and Its First For Wound Drains with ROi BELGRADE, MT, - June 13, 2011 - Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: BONE), a creator and developer of revolutionary bone graft
Read more →Competitive Position
How XTNT ranks across every disease it competes inCompetitive Position is a premium feature
See how XTNT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial